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ABSTRACT
The pregnane X receptor is a nuclear receptor, functioning as a ligand activated
transcriptional factor. PXR is recognized as a major regulator of xenobiotic
metabolism. Several important Phase I and Phase II enzymes, and drug transporters
are regulated by PXR. PXR is also a master regulator of CYP3A4, which is one of the
most important enzymes in drug metabolism. Thus, knowledge of regulation of PXR
expression is crucial to understand alterations in drug metabolism. Many liver diseases
such as steatosis and inflammatory liver diseases alter the expression of drug
metabolizing enzymes and transporters. CYP3A4 is down-regulated in these diseases.
Endoplasmic reticulum (ER) stress is recognized as one important cause of the
diseases and it also accompanies with other diseases such as viral infections. ER stress
is also interconnected with inflammation. CYP3A4 and some other P450 enzymes are
also down-regulated in inflammation. Since PXR is the master regulator of CYP3A4,
this dissertation investigated the effect of ER stress on the PXR expression and its
consequence on PXR-mediated CYP3A4 induction. Thapsigargin and brefeldin A
were used to induce ER stress in cell cultures. ER stress down-regulated the
expression of PXR in primary hepatocytes and HepG2 cells by repressing
transcription. A promoter study revealed that the HNF4α protein level decreased in
ER stress whereas C/EBPβ LIP increased. HNF4α and C/EBPβ were bound to the
promoter of PXR suggested that both HNF4α and C/EBPβ involved in downregulation of PXR by ER stress. PXR-mediated CYP3A4 induction significantly
decreased in ER stress. ER stress also induced the expression of IL-6 in primary
hepatocytes. This finding established an interconnection between ER stress and

inflammation. Interestingly, IL-6 also repressed PXR expression at the same
regulatory sequences as thapsigargin. Furthermore, it has been shown elsewhere that
some other nuclear receptors are regulated by microRNAs (miRNAs). miRNAs
regulate gene expression at the post-transcriptional level, adding complexity to the
gene regulation. This dissertation identified a miRNA that regulated the expression of
PXR. miR-30c-1 down-regulated PXR. miR-30c-1 interacted at the 3’-UTR of PXR
and decreased the PXR mRNA level. The potential binding site of miR-30c-1 on the
3’-UTR of PXR was located.
In summary, ER stress, which is the cause and consequence of several
diseases, down-regulated the expression of PXR. As a result, CYP3A4 induction by
PXR was reduced. Since CYP3A4 and some others drug metabolizing enzymes
regulated by PXR are crucial in drug metabolism, ER stress may alter metabolism of
drugs, leading to increasing drug toxicity or decreasing drug efficacy. miR-30c-1
regulated the expression of PXR, adding complexity to the regulation on PXR.
Although the regulation on the expression of miR-30c-1 is not known, miR-30c-1
might be related to diseases or biological conditions that could eventually affect PXR
expression.
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PREFACE
This dissertation is writing in the manuscript format. Chapter 3 “Suppression
of the pregnane X receptor during endoplasmic reticulum stress is achieved by downregulting hepatocytes nuclear factor-4α and up-regulating liver-enriched inhibitory
protein” is prepared for submission to the Journal of Biological Chemistry. Chapter 4
is prepared for submission.
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CHAPTER 1 INTRODUCTION
1 Pregnane X receptor
The pregnane X receptor (PXR or SXR) is the member of the nuclear receptor
superfamily. PXR is categorized in subfamily 1, group I and member 2 (NR1I2). The
human PXR gene is located on chromosome 3q12q13.3. The gene consists of ten
exons, including exon 1a, 1b, 2, 3, 4, 5, 6, 7, 8, and 9. PXR is highly expressed in the
liver, small intestine, and colon. It is also found in others tissues including, the lung,
stomach, peripheral blood monocytes, blood-brain barrier, uterus, placenta, breast,
osteoclasts, adrenal gland, ovary, heart, and specific regions of the brain (Bauer et al.,
2004 and Lamba et al., 2004a, b).
Several decades ago, exogenous steroids were shown to modulate expression
of cytochrome P450 enzymes (P450s) that protect human and animals against toxic
substances. The expression of the P450 enzymes is induced by several xenobiotic
steroids such as pregnenolone-16α-carbonitrile (PCN) and the enzymes metabolize
both natural and synthetic compounds including herbal and synthetic drugs. PXR was
discovered due to some evidence related to glucocorticoids, a class of steroid
hormones, and the glucocorticoid receptor (GR). PXR was first identified as the
nuclear receptor that induces CYP3A4 expression. Before the discovery of PXR, it
was known that CYP3A and some other P450 enzymes were induced by the
glucocorticoids such as dexamethasone. It was believed that this induction was
mediated through GR. However, PCN which is an anti-glucocorticoid is shown to
induce rat CYP3A (Schuetz and Guzelian, 1984). In addition, treatment with
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dexamethasone and PCN shows a synergistic effect, inducing CYP3A in rat
hepatocytes (Burger et al., 1992). This evidence suggested that there was another
signaling pathway that induced CYP3A other than the glucocorticoid receptor
pathway and led to the discovery of human PXR (Bertilsson et al., 1998, Kliewer et
al., 1998, Lehmann et al., 1998).
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2 Structure of PXR
PXR shares a common structure to the nuclear receptors (NR), containing a
DNA binding domain (DBD), a ligand binding domain (LBD), and an activation
function domain 2 (AF-2). The DBD of PXR is highly conserved in mammals, sharing
more than 94% of their amino acid sequences (Fig. 1-1) (Kliewer et al., 2002). The
DBD contains 2 zinc fingers, approximately 70 amino acids. The DBD of PXR can
recognize and

Fig. 1-1 Sequence comparison of PXR among species. The human glucocorticoid
receptor is shown for comparison.

bind to a specific DNA sequence so called PXR responsive elements (XREMs). The
LBD of PXR contains about 250 amino acids. In contrast to other nuclear receptors,
the LBD of PXR is diverse across species. The LBD of human and mouse PXR shares
3

only 76% amino acid identity. The LBD can fold to form a hydrophobic pocket which
can bind to a wide range of ligands. The AF-2 domain, located at the C-terminal, is
responsible for the dimerization and transcriptional activation. Several isoforms of
PXR have been identified. Some certain isoforms are generated due to alternative
splicing and usage of an alternative start codon on exon 1a or 1b. hPXR (hPAR-1,
SXR), the most abundant isoform of human PXR (about 93.04% of total PXR in the
human livers), contains 434 amino acids. The hPXR transcript contains exon 1a but
not 1b and uses the start codon in exon 2. Next, hPXR.2 is the most abundant
alternative isoform of PXR (approximately 6.7% of total PXR in the human livers),
lacking 111 nucleotides and deleting 37 amino acids from the PXR LBD (Lamba et
al., 2004). Thus, hPXR.2 contains 397 amino acids. hPAR-2, which is created by
alternative splicing using exon 1b but not 1a, uses initiation codon in exon 1b. hPAR-2
is 473 amino acids with an additional 177 nucleotides compared to hPXR (Bertilsson
et al., 1998). In the fourth place, PXR.3 lacks 123 nucleotides, deleting 41 amino acids
from the LBD compared to hPXR. As a result, hPXR.3 contains 393 amino acids.
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3 Function of PXR
PXR functions as a ligand-activated transcriptional factor. It is found to
heterodimerize with the retinoid X receptor-α (RXRα). The PXR/RXR heterodimer
can recognize and bind to the PXR responsive element (XREM). XREM contains 2
half sites and spacer sequences on a promoter of a target gene. XREMs include direct
repeat 3 (DR-3), direct repeat 4 (DR-4), everted repeat 6 (ER-6), and everted repeat 8
(ER-8) elements. The PXR/RXR heterodimer can also be found with or without
promoter binding (Noble et al., 2006). Without a ligand, PXR is associated with
transcriptional corepressors such as nuclear corepressor 1 (NCoR1) and NCoR2,
resulting in repression of transcription (Ding et al., 2005 and Staudinger et al., 2011).
PXR ligands such as rifampicin (RIF) can bind to the LBD of PXR. Following ligand
binding, the AF-2 helix undergoes a conformational change leading to dissociation of
corepressors and recruitment of coactivators such as steroid receptor coactiavator 1
(SRC-1). SRC-1 has intrinsic histone acetyltransferase activity, resulting in chromatin
remodeling and transcriptional activation (Kliewer et al., 1998). The figure 1-2 shows
schematic diagram of the mechanistic function of PXR.
PXR is bound and activated by various xenobiotics and endobiotics. 17-βestradiol, progesterone, and progesterone are examples of endobiotics activating PXR
(Blumberg et al., 1998). A number of genes in Phase I and II enzymes, and drug
transporters have been identified as PXR target genes. These enzymes and transporters
serve as defense mechanisms, transforming and eliminating xenobiotics form bodies.
Therefore, PXR is recognized as a key regulator of xenobiotic metabolism. There are
studies proving that PXR is a master regulator of CYP3A. PCN, which is known to
5

induce CYP3A in mice, does not induce CYP3A in mice lacking PXR (Xie et al.,
2000). High induction of CYP3A is observed when transgenic mice expressing PXR
are treated with rifampicin, proving that PXR regulated CYP3A expression. PXR is a
master regulator of CYP3A which is one of the most important Phase I enzyme
subfamily. The ensuing discussion will provide more details of the roles of PXR in
drug metabolism.

Fig. 1-2 A mechanistic diagram for PXR activity. The figure shows activation of PXR
by rifampicin and subsequent transcriptional activation of the CYP3A4 gene
(LeCluyse, 2001).
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4 Ligand promiscuity and species differences of PXR
A number of compounds, including drugs, herbal medicines, environmental
pollutants and endobiotics, have been identified to activate PXR. It has been shown
that PXR ligands are structurally diverse (Fig. 1-3 and Table 1-1). Examples of PXR
agonists are rifampicin, clotrimazole, phenobarbital, troglitazone, lithocholic acid,
hyperforin, and paclitaxel (Kliewer et al., 2002). The ligand promiscuity of PXR is
explained by characteristics of PXR binding pocket. The ligand binding pocket of
PXR is larger than many other nuclear receptors (Kumar and Thompson, 1999 and
Watkins et al., 2001). It has been estimated that the binding pocket volume ranges
from 1200 Angstroms in the absence of ligands to about 1600 Angstorms in the
presence of rifampicin (di Masi et al., 2009 and Moore et al., 2003). Thus, the binding
pocket is large and also flexible. The species-specific activation of PXR by certain
compounds has been demonstrated. For example, pregnenolone 16α-carbonitrile
(PCN) is a strong PXR agonist of mouse and rat PXR but it does not activate human
or rabbit PXR. Dexamethasone strongly activates mouse PXR and also moderately
activates human PXR. In contrast, rifampicin and phenobarbital activate human PXR
but show very little effect on mouse and rat PXR (Jones et al., 2000). In addition,
transgenic mice possessing human PXR responds to rifampicin, resulting in high
induction of CYP3A by rifampicin (Xie et al., 2000). This evidence proves that the
species-specific induction of CYP3A by rifampicin is due to differences in the amino
acid sequences of PXR. An amino acid mutation in the LBD of PXR can alter
activation of PXR by rifampicin and PCN both in mice and human (Ostberg et al.,
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2002). This study supports that the species-specific induction is due to the differences
in the LBD.

Fig. 1-3 PXR ligands. All compounds except ET-743 are PXR agonists. ET-743 is a
PXR antagonist (Kliewer et al., 2002).
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5 PXR in drug metabolism and detoxification
Human and animals have been always exposed to xenobiotics, including drugs,
environmental pollutants, and naturally-occurring compounds. Our bodies have been
evolved to employ various mechanisms to transform and detoxify these foreign
compounds. The biotransformation process can be divided into two phases, phase I
and II metabolism. Phase I metabolism involves oxidation, reduction, and hydrolysis
reactions. The cytochrome P450 (CYP or P450) is the most important enzyme
superfamily conducting phase I oxidation reactions. For examples, cytochrome P450
3A subfamily (CYP3A) is responsible for metabolizing approximately 50% of all
clinically approved drugs (Guengerich, 2003 and Redinbo, 2004). CYP3A is also the
most abundant P450 enzyme in the human liver and intestine (Paine et al., 2006). An
important characteristic of CYP enzymes such as CYP2B and CYP3A is that they can
be dramatically induced by xenobiotics. This induction is to response to transform and
detoxify those foreign compounds. CYP3A are also involved in metabolism of highly
toxic and narrow therapeutic window drugs and since many drugs are metabolized by
CYP3A, drug interactions among there drugs are life-threatening. PXR is a key
regulator of CYP3A expression (Bertilsson et al., 1998, Kliewer et al., 2002, and
Lehmann et al., 1998). PXR can be activated by a wide range of structurally diverse
compounds and then transactivate CYP3A gene, increasing CYP3A expression.
CYP3A can metabolize a wide range of compounds which correlates with the
promiscuity of PXR. In human, CYP3A4 is the most abundant CYP3A isoforms. PXR
also regulates CYP2B6, CYP2C9, and CYP2C19. Therefore, PXR involves in
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metabolism of a number of xenobiotics, including drugs toxic substances, and
supplements. Examples of compounds that activate PXR and are shown in table 1.
Table 1-1 Drugs activating human PXR
Drug
Clotrimazole
Dexamethasone
Lovastatin
Nifedipine
Paclitaxel
Phenobarbital
Rifampicin
Ritonavir
St. John’s wort
Spironolactone
Tamoxifen
Troglitazone
Warfarin

Therpeutic use
Antimycotic
Anti-inflammatory
Antihypercholesterolemic
Antihypertensive
Anticancer
Anticonvulsant, sedative
Antibiotic
HIV-protease inhibitor
Antidepressant
Antihypertensive
Anticancer
Antidiabetic
Anticoagulant

PXR also regulates important genes in phase II metabolism. Phase II enzymes
generally increase hydrophilicity of xenobiotics by conducting conjugation reactions
of hydrophilic groups to a compound. Substrates of Phase II enzymes can be either
metabolites from Phase I enzymes or compounds which are not metabolized by Phase
I enzymes. The substrates will be conjugated with charged species such as sulfate,
glucuronic acid, and glutathione (GSH). This is to enhance their excretion into urine or
bile and the products from Phase II reactions tend to be less active than the substrates.
PXR has been shown to regulate some isoforms of sulfotransferase (SULT), UDPglucoronosyltransferase (UGTA), and glutathione-S-transferase (GST) (Xu et al.,
2005).

10

Xenobiotic biotransformation is also regulated by uptake and efflux
transporters. Some certain drug transporters have been shown to be regulated by PXR.
PXR is a major regulator of multidrug resistant protein-1 (MDR1, P- glycoprotein, Pgp) (Mills et al., 2004). PXR also control expression of other transporters such as
resistance- associated protein 2 (MRP2), MRP3, MRP4, MRP5
Table 1-2 PXR target genes in humans involved in drug metabolism. CYP7A1
involves in bile acids synthesis.
Target gene
CYP1A1
CYP1A2
CYP1A6
CYP2B6
CYP2B10
CYP2C9
CYP2C19
CYP3A4
CYP3A11
CYP7A1
CYP11A1
CYP11B1
CYP11B2
Sult2A1
UGT1A1
UGT1A3
UGT1A4
MDR1
MRP2

Effect on target gene
Induction
Induction
Induction
Induction
Induction
Induction
Induction
Induction
Induction
Repression
Induction
Induction
Induction
Induction
Induction
Induction
Induction
Induction
Induction

and organic anion transporting polypeptide 2 (OATP2) (Jigorel et al., 2006 and
Schrenk et al., 2001). This information, altogether, shows that PXR regulates a
number of genes involved in drug adsorption, distribution, metabolism, and
elimination (Fig. 1-4). These genes are controlled by PXR in response to xenobiotic
11

challenge so that our bodies can detoxify and eliminate potentially toxic compounds
from the bodies. Since PXR regulates a number of genes involved in drug metabolism,
what could happen if the PXR expression level is altered? The ensuing discussion will
provide more details of certain conditions and factors that could alter PXR expression.

Fig. 1-4 Following ligand binding, PXR binds to XREM of the target genes resulting
in transcriptional activation. The PXR target genes involve in drug adsorption,
distribution, metabolism, and elimination (Ma et al., 2008).
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6 PXR mediated drug-drug interactions
PXR functions as a xenobiotic sensor binding to its ligand and activating
transcription of the target genes which result in increasing drug metabolizing enzymes
that can metabolize the ligand and also other compounds. Drug interactions frequently
occur when multiple drugs are administered such as anti-HIV and anti-tuberculosis.
Discovery of PXR reveals molecular mechanism of how one drug increases clearance
and decrease therapeutic efficacy of a co-administered drug. Thus, PXR directly
involves in drug interactions and causes important clinical implication. There are
several examples of PXR mediated drug-drug interactions. Rifampicin is an antituberculosis drug that is usually used for several months in tuberculosis patients and it
induces CYP3A4 expression. Midazolam is a short-acting sedative drug used as a
premedication for sedation before minor surgical procedures, treatment of acute
seizures, and insomnia. It has been shown that midazolam is not effective with patients
treated with rifampicin. This is because midazolam is mainly metabolized by CYP3A
and rifampicin induces CYP3A expression. Pretreatment with rifamycin, an antituberculosis drug, or rifampicin can dramatically decrease therapeutic efficacy of antiHIV protease inhibitors (i.e. indinavir and nelfinavir), resulting in loss of HIV
suppression (Niemi et al., 2003).
PXR not only involves in drug-drug interaction but also herb-drug interactions.
St John’s wort is an herbal medicine that is widely used for depression, sleep
disorders, and anxiety. St John’s wort contains PXR ligands such as hyperforin and
therefore induces CYP3A expression (Moore et al., 2000). St John’s wort caused
serious herb-drug interaction with cyclosporine, an immunosuppressant used in organ
13

transplant patients to decrease the risk of organ rejection. It has been reported that
organ transplant failed in patients using St John’s wort with cyclosporine. Since the
herb induces CYP3A and cyclosporine is metabolized by CYP3A. As a result,
cyclosporine blood levels decreased, so it was not effective (Murakami et al., 2006
and Mai et al., 2004).
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7 PXR and inter-individual variability in drug response
CYP3A are major enzymes contributing to a large portion of metabolism of
drugs and herbal medicines. CYP3A expression in the human liver and intestine varies
as much as 40 folds (Lamba et al., 2002). It is predicted that 90% of the variation in
CYP3A4 activity is due to genetic factors (Ozdemir et al., 2000). Genetic variation in
the CYP3A4 gene has been extensively studied; however, the genetic variation in the
CYP3A4 gene alone fails to explain the large variability of CYP3A4 expression
(Lamba et al., 2002). Since PXR is the major transcriptional regulator of CYP3A4 it
has been thought that the variability in the PXR expression and the PXR gene could
contribute to the variability in the CYP3A4 expression. Some studies have shown that
there is significant correlation between the PXR and CYP3A4 expression. In the
human livers, the PXR mRNA level is associated with CYP3A4 mRNA (Lamba et al.,
2010).
The expression of PXR has been associated to metabolism and elimination of
certain drugs in human. Atazanavir, a HIV protease inhibitor, is metabolized by
CYP3A4 and MDR1, which are the PXR target genes. Plasma clearance of atazanavir
is associated with a PXR SNP, rs2472677 (Siccardi et al., 2008, Schipani et al., 2010).
The study shows that patients with homozygous T allele exhibit higher atazanavir
clearance than those with C allele. In addition, The SNP rs2472677 has previously
been reported that it is also associated with PXR and CYP3A4 expression in the
human livers (Lamba et al., 2008). Thus, the association between atazanavir clearance
and the PXR SNP is likely due to expression of PXR and its target gene CYP3A4. A
human study shows that a haplotype of the PXR gene is associated with doxorubicin
15

clearance (Sandanaraj et al., 2008). The study is conducted in Asian populations
(Chinese, Malay and Indian) and the result shows that the haplotype is correlated with
the expression of PXR and its downstream target genes CYP3A4 and MDR1. The
haplotype is associated with reduced doxorubicin clearance. These studies suggest that
PXR involves in inter-individual variability in drug response of certain drugs. The
expression of PXR is related to the drug clearance.
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8 Endoplasmic reticulum stress in diseases and drug metabolism
Endoplasmic reticulum (ER) is an organelle in eukaryotic cells that serve
several functions, including protein synthesis, folding and trafficking, posttranslational modification, calcium storage and regulation, and xenobiotic metabolism.
Newly synthesized proteins translocate to the ER where they are folded into the
functional structures. The ER also functions as the calcium storage which responds to
stimuli that alter cellular energy level or redox status. Some certain conditions such as
oxidative stress, viral infection, and inflammation can disrupt the ER function and
cause stress in ER (Zhang and Kaufman, 2008). ER stress occurs when there is
accumulation of unfolded or misfolded proteins in ER. Accumulation of these
unfolded proteins can be caused by an increase of demand for protein folding or
disruption of reactions of protein folding. In mammalian cells, the ER responds to
stress by triggering unfolded protein response (UPR), which is signaling pathway
aiming to relief the stress from the ER and to resume its function. Generally, the UPR
will activate signaling pathways that lead to increasing expression of molecular
chaperones involved in protein folding. UPR also increase protein degradation to
remove unfolded or misfolded proteins. Protein translation is also reduced to decrease
influx of new proteins into the ER (Xu et al., 2005). In mammalian cells, the UPR
signaling pathways are initiated by ER protein double-stranded RNA-dependent
protein kinase-like ER kinase (PERK), activating transcription factor 6 (ATF6), and
inositol-requiring 1α (IRE1α). All three proteins are up-regulated during ER stress and
have been used as indicators of stress in ER. Also, IRE1 is a ribonuclease that can
splices X box-binding protein 1 (XBP1) mRNA. In ER stress, IRE1 splices XBP1
17

mRNA, producing spliced XBP1 mRNA that will be translated to XBP1 protein that
induces UPR target genes such as chaperones. Thus, the presence of spliced XBP1
mRNA has also been used as an ER stress indicator. When the stress in the ER
prolongs and cannot be relived, apoptosis is triggered. The UPR is an adaptive
program responding to stimuli. The ER stress-induced apoptosis can be considered as
a mechanism to protect tissues and organs by eliminating the stressed cells that
produce malfunctioning proteins.
It is recognized that ER stress and UPR implicate in various diseases, including
inflammatory diseases, metabolic diseases, neurodegenerative diseases, and cancer
(Wang and Kaufman, 2012 and Yoshida, 2007). One reason is because ER stress and
UPR can cause apoptosis and may damage functioning tissues. Secondly, the UPR
alters expression of many genes. Thus, ER stress and UPR have been extensively
studied in pathological aspects of several diseases. The liver is the major organ
responsible for drug metabolism. Many diseases can impair liver functions such as
decreasing capability of xenobiotic detoxification. ER stress has been associated with
these diseases such as diabetes and steatosis (Kolwankar et al., 2007). However,
studies of ER stress related to drug metabolism are lacking and there are only few
studies about P450 enzymes. In rat hepatocytes, ER stress down-regulates CYP3A
(Acharya et al., 2009). Nevertheless, effect of ER stress on many of Phase I and II
enzymes and drug transporters has not been investigated. In addition, effect of ER
stress on PXR and most of PXR target genes has not been reported.
There is evidence showing that there would be connections between ER stress
and drug metabolism. Furthermore, several studies demonstrated that there is cross18

talk between UPR and inflammation (Adolph et al., 2012, Zhang and Kaufman, 2008).
The link between UPR and inflammation involves NF-κB signaling pathway and
inflammatory cytokines. The inflammatory cytokines such as interleukin-1 (IL-1β),
interleukin-6 (IL-6), tumor necrosis factorα (TNFα) are pro-inflammatory cytokines
that can lead to inflammation. It has been reported that thapsigargin, a natural
compound which is widely used to induce ER stress in cell culture, induced IL-6
expression in rat peritoneal macrophages (Ichinowatari et al., 2002). The study
showed the link between ER stress and inflammation and the inflammatory cytokine
such as IL-6 in rat. In addition, the inflammatory cytokines are known to downregulate P450 enzymes. Therefore, ER stress and UPR could affect P450 enzyme
expression. Effect of inflammation on drug metabolism is explained in a following
topic.
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9 Effect of Inflammation on PXR and drug metabolism
Inflammation is a response to harmful stimuli such as infection by pathogens
or tissue injuries from physical or chemical damages. Inflammation can occur in short
term (acute inflammation) about a few days or long term (chronic inflammation)
which can last for months or years. Inflammation at organs involving in drug
metabolism such as the liver and small intestine can cause a large impact on drug
metabolism. This is because the pro-inflammatory cytokines such as IL-1β, IL-6, and
TNFα alter expression of drug metabolizing enzymes. Both in humans and animals,
inflammation causes changes in the expression levels of several P450 in the liver and
small intestine as well as other organs such as the kidney and brain (Morgan, 1997,
Renton, 2004). In most cases, the expression of P450 enzymes is suppressed due to
inflammation. These decreases in the P450 enzymes significantly alter drug
metabolism and can cause serious clinical consequences especially for drugs with a
narrow therapeutic index. Therefore, inflammation can increases drug toxicities.
It is known that interleukin-6 (IL-6), a pro-inflammatory cytokine, downregulates CYP3A4, 2B6, 2C9, and 2C19 expression in human hepatocytes (Aitken et
al., 2007). PXR which regulates these P450 enzymes is also down-regulated by IL-6 in
human hepatocytes (Pascussi et al., 2000). The information of inflammation together
with ER stress from the previous topic suggests that ER stress may affect PXR
expression and function.
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10 microRNA
A 3’-untranslated region (3’-UTR) of mRNA is involved in several gene
regulatory processes, including mRNA stability, transcript cleavage, translation, and
mRNA localization. It is a binding site of many regulatory proteins and microRNA
(miRNA) (Barrett et al., 2012). The length of the 3’-UTR in mammalian mRNA varies
from 60 – 4000 nucleotides. The average length of the 3’-UTR in human genes is
about 740 nucleotides which are longer than that in other mammalian and vertebrate
genes (420 – 500 nucleotides) and in plants and fungi (240-274 nucleotides) (Pesole et
al., 1997). The longer 3’-UTR in human suggests that human has evolved to possess
more complexity of post-transcriptional control which is another important step to
regulate gene expression.
miRNA is a short single strand RNA about 21-23 nucleotides. It is transcribed
by RNA polymerase II (pol II) in the nucleus as long primary transcripts (pri-miRNA)
(Kim, 2005). These transcripts can be several kilobases in length. miRNA is contained
in pri-miRNA as a stem-loop hairpin structure about 60-80 nucleotides. This miRNA
hairpin in pri-miRNA are recognized and excised by a microprocessor protein
complex. The miRNA hairpin (pre-miRNA) is transported to the cytoplasm and
further processed. The hairpin portion of pre-miRNA is excised by an RNase III
enzyme dicer, producing a 21-23 nucleotide duplex. The miRNA duplex is
incorporated into the RNA-induced silencing complex (RISC). One strand of the
miRNA duplex is degraded, leaving the other strand in the RISC complex. miRNA in
the RISC complex serves as a guide that directs RISC to target mRNAs. Binding of
miRNA-RISC complex to mRNA results in blocking translation or cleaving of the
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target mRNA (Bartel, 2004).

Thus, miRNAs function as post-transcriptional

regulators. There is growing evidence showing that many miRNAs can both repress
translation and degrade mRNA (Lee et al., 2012). miRNA has been shown to target at
the 3’-untranslated region (3’UTR) of mRNA. It has been estimated that human may
encode more than 1000 miRNAs (Bartel, 2009). Approximately 70% of miRNAs are
located in introns or exons and about 30% are located in intergenic regions (Rodriguez
et al., 2004). At present, biological functions of most miRNAs are not known. The role
of miRNAs is thought to be for fine-tuning of gene expression (Sevignani et al., 2006).
In addition, it is predicted that a gene can be targeted by several miRNAs and binding
sites of those miRNAs might overlap (John et al., 2004). miRNAs have been
associated with several types of cancers, genetic diseases, and inflammatory diseases.
miRNAs have been extensively studied; however, identifying and validating miRNA
targets is still challenging. Many in silico algorithms have been developed to predict
targets and binding sites of miRNAs but they still predict a large number of false
positives (Da Costa Martins and De Windt, 2012). Certain approaches have been used
to validate miRNA targets. For instance, a plasmid-based reporter system is used to
identify targets and binding sites of miRNAs. Generally, A 3’-UTR of a gene of
interest is fused downstream of a luciferase reporter open reading frame. In case that a
miRNA can bind to the 3’-UTR of the gene, luciferase expression will be reduced
compared to the control.
miRNAs have been shown to involve in regulation of various biological
processes such as cell proliferation, tumor development, immune response,
metabolism, and disease development. Several groups have demonstrated that
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expression of some certain nuclear receptors and liver-enriched proteins are regulated
by miRNAs. For example, GR receptor is regulated by miR-18 and miR-124a
(Vreugdenhil et al., 2009). Estrogen receptor-α (ERα) is regulated by miR-206
(Adams et al., 2007), miR-221, miR-222 (Zhao et al., 2008), and miR-22 (Xiong et al.,
2010). Hepatocyte nuclear factor 4α (HNF4α), an important transcriptional factor
regulating several genes in the liver, is regulated by miR-24 and miR-34a (Takagi et
al., 2010). PXR has been shown to be regulated by miR-148a (Takagi et al., 2008).
miR-148a decreased PXR expression and attenuated PXR-mediated CYP3A4
induction in vitro. In fact, a number of miRNAs have been computationally predicted
to bind to PXR mRNA (microRNA.org, 2013). Other nuclear receptors such as ERα
and HNF4α are also regulated by more than one miRNA. Thus, PXR might be
regulated by some other miRNAs other than miR-148a.
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CHAPTER 2 STATEMENT OF PURPOSE
It has been shown in human that certain liver diseases involving inflammation
such as viral hepatitis and steatosis decrease the liver’s capability to metabolize a
number of drugs. CYP3A4 expression is also decreased in these diseases. PXR is
recognized as a xenobiotic sensor, binding to a wide range of compounds and
functioning as a ligand-activated transcriptional factor. PXR regulates many important
genes in drug metabolism, including drug metabolizing enzymes such as CYP3A and
drug transporters such as MDR1. CYP3A4 is a major isoform of the CYP3A
subfamily responsible for metabolizing about 50% of marketed drugs. CYP3A4 is
known to possess high inter-individual variability in expression due to several
contributing factors such as genetic and disease related factors. Variation in CYP3A4
expression has been shown to affect therapeutic efficacy and adverse reaction of
drugs. CYP3A4 expression and activity in humans is significantly associated with
PXR expression. Therefore, alteration in PXR expression has been accepted as a cause
of interindividual variability in CYP3A (Sandanaraj et al., 2008 and Urguhart et al.,
2007). Nevertheless, factors causing changes in PXR expression have not been clearly
understood. This dissertation studies certain factors altering the PXR expression which
may lead to variability in CYP3A expression.
The goal of Chapter 3 of this dissertation is to study effect of ER stress on
PXR expression and function. ER stress has been linked to chronic liver diseases such
as steatosis and type 2 diabetes. These liver diseases have been shown to alter capacity
of drug elimination. CYP3A4 is an example of drug metabolizing enzymes that is
known to decrease in the chronic liver diseases. However, the effect of ER stress on
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PXR, which is the major regulator of CYP3A4, has not been investigated. A
mechanism of how ER stress down-regulates CYP3A4 expression has not been
elucidated. Thus, Chapter 3 will study the effect of ER stress on expression of PXR
and its consequence on induction of CYP3A4. The study will also investigate the
mechanism of how ER stress impacts expression of PXR. The effect of ER stress on
PXR at the transcriptional level will be studied. Since PXR functions as the liganddependent transcriptional factor binding to its ligand and transactivating PXR target
genes, the impact of ER stress on PXR function will be determined by monitoring the
transcriptional level of CYP3A4.
The aim of Chapter 4 of this dissertation is to identify a miRNA that regulates
expression of PXR. miRNA adds complexity of how a gene is regulated by acting on
the mRNA post-transcriptionally. miRNA have been recognized to cause
interindividual variation in a gene expression (Lu et al., 2012). miRNA is also
involved in inflammatory diseases such as inflammatory bowel disease and liver
cancer (Ranjha et al., 2013). Other nuclear receptors such as ERα and HNF4α and
some genes involving in drug metabolism are regulated by miRNA. Certain P450
enzymes have been showed to be regulated by miRNA (Nakajima et al., 2011).
CYP3A4 is regulated by miR-27b and miR-378 regulates CYP2E1 (Pan et al., 2009
and Mohri et al., 2010) miR-148a has been identified to target at the PXR mRNA
(Takagi et al., 2008). It is predicted that a gene can be targeted by several miRNAs
(John et al., 2005). Identifying a miRNA that regulates PXR will further improve
knowledge of how PXR is regulated. A target site of miRNA on PXR will be
identified and the effect of miRNA on PXR expression will be studied.
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Since ER stress is related to the diseases and could have an impact on drug
metabolism, studying the effect of ER stress on PXR, the master regulator of
xenobiotic metabolism, could help understand the effect of ER stress on PXR and drug
metabolism. The study may reveal the mechanism of regulation of PXR. Identifying
miRNA regulating PXR could provide a better understanding of the regulation on
PXR. These studies may provide a better understanding in alteration in PXR
expression and its effect on drug metabolism.

34

REFERENCES
John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS (2004) Human
MicroRNA targets. PLoS Biol. 2(11):e363.

Lu J, Clark AG (2012) Impact of microRNA regulation on variation in human gene
expression. Genome Res. 22(7):1243-54.

Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, Yokoi T (2010) Human
CYP2E1 is regulated by miR-378. Biochem Pharmacol. 79(7):1045-1052.

Nakajima M, Yokoi T (2011) MicroRNAs from biology to future pharmacotherapy:
regulation of cytochrome P450s and nuclear receptors. Pharmacol Ther. 131(3):330-7.

Pan YZ, Gao W, Yu AM (2009) MicroRNAs regulate CYP3A4 expression via direct
and indirect targeting. Drug Metab Dispos. 37:2112-117.

Ranjha R, Paul J (2013) Micro-RNAs in inflammatory diseases and as a link between
inflammation and cancer. Inflamm Res. Feb 17 [Epub ahead of print].

Sandanaraj E, Lal S, Selvarajan V, Ooi LL, Wong ZW, Wong NS, Ang PC, Lee EJ,
Chowbay B (2008) PXR pharmacogenetics: association of haplotypes with hepatic
CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian
breast cancer patients. Clin Cancer Res. 14(21):7116-26.

Takagi S, Nakajjima M, Mohri T, Yokoi T (2008) Post-transcriptional regulation of
human pregnane X receptor by micro-RNA affects the expression of cytochrome P450
3A4. J Biol Chem. 283:9674-80.

Urguhart BL, Tirona RG, Kim RB (2007) Nuclear receptors and the regulation of
drug-metabolizing enzymes and drug transporters: implications for interindividual
variability in response to drugs. J Clin Pharmacol. 47(5):566-78.

35

CHAPTER 3
MANUSCRIPT 1: formatted for the journal of biological chemistry

SUPPRESSION OF THE PREGNANE X RECEPTOR DURING
ENDOPLASMIC RETICULUM STRESS IS ACHIEVED BY DOWNREGULATING HEPATOCYTE NUCLEAR FACTOR-4 AND UPREGULATING LIVER-ENRICHED INHIBITORY PROTEIN

Abbreviations: BFA, Brefeldin A; C/EBP, cytidine-cytidine-adenosine-adenosinethymidine enhanced binding protein-; CYP3A4, cytochrome P450 3A4; DMEM,
Dulbecco’s

modified

eagle

medium;

GAPDH,

glyceraldehyde-3-phosphate

dehydrogenase; HNF-4, Hepatocyte nuclear factor-4; LAP, Liver-enriched
activator protein; LIP, Liver-enriched inhibitory protein; PXR, pregnane X receptor;
RT-qPCR, reverse transcription-quantitative polymerase chain reaction; Thaps,
thapsigargin; XBP1, X-box binding protein 1 gene.
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ABSTRACT
ER-stress is recognized as a common theme in the development of metabolic
syndrome and other diseases. Chronic liver diseases develop ER-stress and also show
decreased capacity of drug metabolism. The pregnane X receptor (PXR) is a master
regulator of genes involved in drug elimination.

This study was performed to

determine whether ER-stress condition decreases the expression of PXR and whether
the decrease alters the induction of cytochrome P450 3A4 (CYP3A4).

Primary

hepatocytes and HepG2 cell line (human hepatocellular carcinoma) were treated with
brefeldin A and thapsigargin, two well-established ER-stressors. Without exception,
both stressors significantly decreased the expression of PXR. The decrease led to
reduced induction of CYP3A4. Reporter dissection, electrophoretic mobility shift
assay and chromatin immunoprecipitation located in the PXR promoter region two
adjacent elements recognized by hepatocyte nuclear factor-4 (HNF-4) and cytidinecytidine-adenosine-adenosine-thymidine enhanced binding proteins (C/EBP proteins),
respectively.

Over-expression of HNF-4 or liver-enriched activator protein (an

activator of C/EBP) restored the expression of PXR. Interestingly, the very same
sequence also responded to interleukin-6 (IL-6), and primary hepatocytes treated with
thapsigargin significantly increased the level of IL-6 mRNA. These findings establish
a functional interconnection between ER-stress and signaling of proinflammatory
cytokines in the regulated expression of PXR.
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1. INTRODUCTION
The endoplasmic reticulum (ER) is an organelle involved in diverse cellular functions
including

protein

synthesis/transportation,

membrane

generation,

calcium

concentration regulation and xenobiotic metabolism (Johnson et al., 2012; Li et al.,
2012).

Therefore, ER homeostasis is critical in maintaining the overall cellular

functions. On the other hand, many factors such as oxidative stress disrupt ER
homeostasis, leading to ER stress (Cali et al., 2011; Adolph et al., 2012; Xu and Zhu,
2012). While the precise mechanisms of ER-stress remain to be determined, one of
the outcomes is the accumulation of unfolded proteins in the ER (Benbrook and Long,
2012; Haeri and Knox, 2012). The unfolded protein response (UPR), occurring at the
initial stage of ER-stress, is triggered to slow down protein synthesis, improve protein
folding capacity and enhance degradation of unfolded proteins.

Nevertheless,

persistent ER-stress has been linked to the development of various conditions such as
type 2 diabetes and chronic liver diseases (Back and Kaufman, 2012; Flamment et al.,
2012; He and Chen, 2012; Pagliassotti, 2012).

The liver is the largest internal organ and plays the primary role in drug metabolism
(Santoro et al., 2007; Bock and Bock-Hennig, 2010; Villarroya et al., 2010). The
prevalence of hepatic dysfunction is high and it affects more than 10% of Americans
(Liver foundation, 2009). Worldwide, liver cancer and chronic liver diseases are the
seventh leading cause of death (IPA, 2007). Many liver diseases are accompanied
with ER-stress and exhibit decreased capacity of drug metabolism and detoxification.
Steatotic livers, for example, were found to have significant decreases in CYP3A
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activity (Kolwankar et al., 2007), the most robust catalytic system in the oxidative
metabolism. In cultured primary hepatocytes, lipid-loading significantly decreased the
expression of CYP3A4 (Donato et al., 2006).

Furthermore, livers from diabetic

patients showed significantly lower expression of CYP3A4 (Dostalek et al., 2011).

The expression of CYP3A4 is regulated by several major transcription factors.
Among these proteins, the pregnane X receptor (PXR) has been established to play the
primary role (Ihunnah et al., 2011). This receptor forms a heterodimer with the
retinoid X receptor- and binds to PXR response elements that contain a half-site
AG(G/T)TCA or related sequence. We and other investigators have functionally
characterized four PXR elements in the CYP3A4 gene and some of the elements
operate in a coordinate manner (Goodwin et al., 1999; Song et al., 2004; Liu et al,
2008; Toriyabe et al., 2009). While PXR regulates the expression of CYP3A4 and
many other drug-eliminating genes, the expression of PXR varies by drugs and disease
mediators. Importantly, the expression of PXR directly affects CYP3A induction.
Dexamethasone, a synthetic glucocorticoid, induces PXR and synergistically induces
CYP3A (Shi et al., 2010).

Likewise, clofibrate, the lipid-lowering agent, causes

super-induction of CYP3A23 (Ma et al., 2005). Conversely, interleukin-6 (IL-6), a
proinflammatory cytokine, decreases PXR expression and reduce CYP3A4 induction
(Yang et al., 2010).
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This study was performed to determine whether ER-stress condition decreases the
expression of PXR and whether the decrease alters the induction of CYP3A4.
Brefeldin A (BFA) and thapsigargin (Thaps), two well-established ER-stressors,
significantly decreased the expression of PXR in both primary hepatocytes and HepG2
cell line (human hepatocellular carcinoma). The decrease led to reduced induction of
CYP3A4.

The decreased expression of PXR was achieved by transcriptional

repression via two adjacent elements recognized by hepatocyte nuclear factor-4
(HNF-4) and cytidine-cytidine-adenosine-adenosine-thymidine enhanced binding
proteins (C/EBP proteins), respectively. Over-expression of either protein restored the
expression of PXR. Interestingly, the adjacent elements also responded to interleukin6 (IL-6), suggesting a functional interconnection between ER-stress and signaling of
proinflammatory cytokines.
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2. MATERIALS AND METHODS
2.1. Chemicals and supplies
IL-6 and Thaps were from R&D Systems (Minneapolis, MN). BFA, Hanks balanced
salt solution and the antibody against glyceradehyde-3-phosphate dehydrogenase
(GAPDH) were from Sigma (St. Louis, MO). Dulbecco’s modified eagle medium
(DMEM) and high fidelity Platinum Taq DNA polymerase were from Life
Technology (Carlsbad, CA). The antibodies against HNF4 or C/EBP were from
Abcam Inc (Cambridge, MA). The goat anti-rabbit IgG conjugated with horseradish
peroxidase was from Pierce (Rockford, IL). Plated human primary hepatocytes were
obtained from the Liver Tissues Procurement and Distribution System (University of
Minnesota) or CellzDirect (Pittsboro, NC). Nitrocellulose membranes were from BioRad (Hercules, CA). Expression constructs were from OriGene Technologies Inc
(Rockville, MD). Unless otherwise specified, all other reagents were purchased from
Fisher Scientific (Fair Lawn, NJ).

2.2. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
Total RNA (1 g) was subjected to the synthesis of the first strand cDNA as described
previously (Xiao et al., 2012). cDNAs were then diluted 8 times and RT-qPCR was
conducted with TaqMan Gene Expression Assay (Applied Biosystems, Foster City,
CA). The TaqMan probes were: PXR, Hs00243666_m1; HNF4, Hs00230853_m1;
C/EBP, Hs00942496_s1; IL-6, Hs00985639_m1; and GAPDH, 4352934E; and RNA
polymerase II, Hs00172187_m1. The normalization of RT-qPCR was performed
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primarily based on the signal of GAPDH mRNA and selective samples were analyzed
for the level of RNA polymerase II to confirm the normalization.

The PCR

amplification was conducted in a total volume of 20 l containing universal PCR
master mixture (10 l), gene-specific TaqMan assay mixture (1 µl), and cDNA
template (6 l). The mRNA levels were normalized according to the level of GAPDH
and the normalization of selected samples was confirmed based on the signal of RNA
polymerase II.

Amplification and quantification were done with the Applied

Biosystems 7500 Real-Time PCR System.

2.3. Reporter constructs and cotransfection assays
PXR promoter reporters were prepared to contain various lengths of PXR genomic
sequence. All promoter reporters were subcloned from the PXR-1286-Luc reporter
through Mlu I and BamH I sites. All cloning and subcloning experiments were
performed by PCR with high fidelity Platinum Taq DNA polymerase. To prepare
reporters with a disruption of the element HNF4, C/EBP, or both, oligonucleotides
with the wild type or mutant sequences were synthesized and annealed. The resultant
double-stranded oligonucleotides were ligated to the pGL3 promoter vector through
Nhe I and Xho I sites. The sequences of oligonucleotides for the reporters are shown
in Table I. All reporter constructs were subjected to sequence analysis. To determine
the reporter activities, cotransfection in HepG2 cells was performed. Transfection
mixtures contained 100 ng of a reporter plasmid and 5 ng of null-Renilla luciferase
plasmid. In some cases, an expression construct was used including HNF4 and
C/EBP in the transfection mixtures. The corresponding vector was used to equalize
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the total amount of plasmid DNA in transfection. Typically, cells were transfected for
24 h and the medium was replaced with fresh medium supplemented with 1% FBS.
The treatment lasted for 24 h and the cells were washed once with phosphate buffered
saline and collected by scraping. The reporter enzyme activities were assayed with a
Dual-Luciferase Reporter Assay System as described previously (Yang et al., 2011).

2.4. Electrophoretic mobility shift assay (EMSA)
The EMSA experiment was performed as described previously (Yang et al., 2012).
Nuclear extracts of HepG2 cells treated with Thaps (50 nM) for 24 h were prepared
with the nuclear and cytoplasmic extraction kit (Pierce, Rockford, IL). The sense and
antisense oligonucleotides (Table I) were annealed by heating at 94°C for 5 min
followed by gradually cooling to room temperature. The sense strand was synthesized
as labeled or non-labeled form (for competition).

Nuclear protein (5 μg) was

incubated with a double-stranded biotinylated probe (0.1 pmol) at room temperature
for 20 min. In competition assays, nuclear extracts were first incubated with an
unlabeled probe at a 25x or 100x excess for 20 min before addition of the labeled
probe. For antibody-disruption assay, the nuclear extracts were first incubated with an
antibody against HNF4 or C/EBP on ice for 20 min and then with the labeled
probe. The protein-DNA complexes were resolved by non-denaturing polyacrylamide
gel electrophoresis (5%) and transferred onto a Biodyne® nylon membrane. The
biotinylated probe was detected with streptavidin-conjugated horseradish peroxidase
and chemiluminescent substrate (PIERCE, Rockford, IL).

The chemiluminescent

signal was captured by KODAK Image Station 2000, and the relative intensities were
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quantified by KODAK 1D Image Analysis Software (KODAK Molecular Imaging
Software, Version 4.0, Rochester, NY).

2.5. Chromatin immunoprecipitation (ChIP)
ChIP experiment was performed, essentially as described previously (Chen et al.,
2012). HepG2 Cells were treated with DMSO or Thaps (50 nM) for 24 h, washed and
underwent cross-linking for 15 min by 1.0% formaldehyde at room temperature, and
the cross-linking was terminated with glycine (final concentration of 125 mM). The
soluble chromatin preparations were prepared as described previously (Chen et al.,
2012). For the ChIP experiment, chromatin preparations were pre-cleared for 2 h at
4°C with protein G beads pre-treated with herring sperm DNA (0.2 mg/ml) and BSA
(0.5 mg/ml). A fraction of the pre-cleared chromatins was stored at -80°C for later use
as an input. An antibody against HNF4 or C/EBP was added into the pre-cleared
chromatins, and an overnight incubation at 4°C was performed. As a negative control,
incubation was performed with pre-immune IgG. The antibody-bound chromatin and
DNA input were analyzed by PCR for the presence of the genomic fragments
containing the HNF4 or C/EBP-bound element with primers shown in Table I. The
PCR was performed with Platinum Taq DNA polymerase for a total of 32 cycles at
94C for 30 s, 58C for 30 s and 68C for 60 s. A 3-min initial denaturation was
performed.
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2.6. Other analyses
Protein concentrations were determined with BCA assay (Pierce) based on albumin
standard. Western blotting was performed as described previously (Shi et al., 2011)
and the preparation of antibodies were described elsewhere (Sachdeva et al., 2003).
Data are presented as mean  SD of at least three separate experiments, except where
results of blots are shown in which case a representative experiment is depicted in the
figures. Statistical significance between two means was made according to One-way
ANOVA followed by a DUNCAN’s multiple comparison test (p < 0.05).
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3. RESULTS
3.1. Down-regulation of PXR by ER-stressors
ER-stress is a phenomenon in various chronic diseases and many PXR-target genes
are down-regulated by disease conditions associated with ER-stress (Cali et al., 2011;
Johnson et al., 2012). To test whether the expression of PXR itself is decreased during
ER-stress, HepG2 cells were treated with Thaps and BFA. Thaps induces ER-stress
by depleting calcium in the ER (Salido et al., 2009), whereas BFA by retrogradetransporting proteins from the Golgi apparatus to the ER (Nickel, 2010). As shown in
Fig. 1A, treatment with either stressor significantly decreased the level of PXR
mRNA. BFA was slightly more potent than Thaps (Fig. 1A). Next, we determined
the decrease of PXR mRNA as a function of the amount of Thaps. As shown in Fig.
1B, Thaps at 1 nM caused a 20% decrease of PXR mRNA and at 10 nM caused a 40%
decrease. Further increased concentrations of Thaps up to 250 nM caused only a 10%
additional decrease (Fig. B).

To ascertain the cellular ER-stress level, semi-

quantitative PCR was performed to detect the presence of spliced XBP1 mRNA (Xbox binding protein 1 gene), a widely used marker for ER-stress (Ri et al., 2012). As
shown in Fig. 1B (bottom), little spliced XBP1 mRNA was detected in cells treated
with solvent or 1 nM Thaps. Comparable levels of spliced and non-spliced XBP1
mRNA were detected in cells treated at 10 nM (Fig. 1B). In contrast, cells treated at
25 or 250 nM exhibited the presence of spliced XBP1 mRNA only. To gain in vivo
relevance, primary hepatocytes were treated with Thaps, and the expression of PXR
was determined. As shown in Fig. 1C, Thaps decreased PXR at both mRNA and
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protein levels, and the decrease was even greater than that in HepG2 cells (Figs. 1A
and 1B).

3.2. Transcriptional repression of PXR by Thaps
The decreases in PXR mRNA pointed to two possibilities: ER-stressors enhanced
PXR mRNA degradation and/or reduced PXR transactivation. To shed light on the
second possibility, various PXR reporters containing the promoter or along with upstream regulatory sequences at varying length were tested for the repression in
response to Thaps. As shown in Fig. 2A, all PXR reporters, compared with the vector
control, were significantly repressed. However, the reporter PXR-56Luc, compared
with PXR-106Luc, was repressed to a significantly less extent, suggesting that the
DNA segment from -106 to -56 nucleotides is critical for the repression. Based on
element predication with computer program, this DNA segment contains an HNF4
and a C/EBP binding site. These two elements are spaced by three nucleotides (Fig.
2A). It should be noted that as many as five transcription start sites (filled triangles in
Fig. 2A) are located in the PXR promoter region (Zhang et al., 2001; Kurose et al.,
2005; Tompkins et al., 2008).

To test whether these two elements support Thaps-repression, element reporters were
prepared to contain this segment or segment with one or both elements disrupted. The
resultant reporters were tested for the abolished response to Thaps. As shown in Fig.
2B, disruption of the HNF4 element largely abolished the repressive response to
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Thaps. In contrast, disruption of the C/EBP element reversed Thaps-repression by
20%.

These results suggested that both HNF4 and C/EBP supported the

transactivation of PXR with HNF4 playing a greater role for the repression. To shed
light on this possibility, cells were transfected with HNF4 or LAP (liver-enriched
activator protein: a form of C/EBP), treated with Thaps, and detected for the level of
PXR mRNA. As shown in Fig. 2C, transfection of HNF4 or LAP reversed the
suppression of PXR mRNA in response to Thaps.

Interestingly, LAP showed a

greater reversal activity than HNF4.

3.3. Effect of Thaps on the expression of HNF4 and C/EBP (LAP and LIP)
The transfection study demonstrated that HNF4 and LAP were positive regulators of
PXR expression. Next we tested whether Thaps decreased PXR expression by downregulating HNF4 and C/EBP. Cells were treated with Thaps and the expression of
HNF4 and C/EBP were determined by RT-qPCR and Western blotting. As shown
in Fig. 3A, Thaps surprisingly caused a 9-11 fold induction of C/EBP mRNA. It has
been well established that C/EBP mRNA produces several in-frame polypeptides
including LAP* (38 kDa), LAP (35 kDa) and LIP (liver-enriched inhibitory protein:
20 kDa) (Tsukada et al., 2011). Importantly, these polypeptides are functionally
distinct with LAP* and LAP being activators and LIP being an inhibitor.

To

determine whether the increased C/EBP mRNA by Thaps differentially increases in
these polypeptides, Western blotting was performed. As shown in Fig. 3A (Right),
little changes were detected on the levels of LAP and LAP*. In contrast, LIP was
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markedly increased. These results established that induction of C/EBP mRNA by
Thaps increased the production of LIP but not activator LAP* and LAP. The level of
HNF4 mRNA, in contrast to the level of C/EBP mRNA, was significantly
decreased by Thaps (Fig. 3B) and the decrease was less with prolonged treatment.
The 12 h time-point showed a 60% decrease whereas the 24 h time-point showed a
40% decrease (Fig. 3B). Consistent with the decease in HNF4 mRNA, the level of
HNF4 protein was drastically decreased (Fig. 3B).

3.4. Occupancy of the PXR promoter by HNF4 and C/EBP
The reporter and expression studies collectively suggested that the PXR promoter is
targeted by HNF4 and C/EBP. To directly test this possibility, EMSA and ChIP
experiments were performed. The EMSA experiment was performed with two probes:
one containing the putative HNF4 site and the other the C/EBP site. As shown in
Fig. 4A, incubation with the HNF4 probe led to the detection of a major shifted band
(Fig. 4A). The intensity of this band was weaker when incubation was performed with
nuclear extracts from Thaps-treated cells, consistent with the fact that Thaps downregulated HNF4. This band was competed by non-labeled probe and abolished by
the antibody against HNF4. Addition of the antibody also intensified the band on the
top of the gel (Fig. 4A). Incubation with the C/EBP probe, on the other hand, led to
the detection of several bands (Fig. 4B). Incubation with extracts from Thaps-treated
cells produced a new shifted band (probably bound by LIP) and decreased the
intensities of two shifted bands (arrowed in column 3). All shifted bands except the
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top one were competed by non-labeled probe but not by the corresponding non-labeled
probe with disrupted C/EBP binding site. Nonetheless, the putative LAP and LIP
binding bands were abolished by the antibody against C/EBP (Fig. 3).

The EMSA experiment established that the PXR promoter contained HNF4 and
C/EBP binding site. Next we tested whether both proteins occupy the PXR promoter.
ChIP experiment was performed in cells treated with solvent or Thaps. In addition to
HNF4 and C/EBP element-containing segment, a segment of the PXR gene
containing either element was subjected to PCR-amplification as a control. As shown
in Fig. 4C, PCR detected the amplification of both segments with input DNA.
However, PCR detected the HNF4-C/EBP but not the control segment with ChIPedDNA. The amplification was observed with ChIPed DNA from control but not Thapstreated cells (Fig. 3C). It should be noted that pre-immune IgG for ChIP experiment
did not yield any amplification.

3.5. Interconnection between Thaps and IL-6 in the suppression of PXR
We have previously showed that PXR was down-regulated by the proinflammatory
cytokine IL-6 (Yang et al., 2010). To determine whether Thaps and IL-6 use similar
genomic sequence in the down-regulation, HepG2 cells were transfected with various
PXR reporters, treated with IL-6 as shown, and detected for luciferase activity. BFA,
another commonly used ER stressor, was also included in this study. As predicted,
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both IL-6 and BFA produced a similar responding pattern as Thaps among these
reporters (Figs, 2A and 5A). Two additional experiments were performed to shed
slight on the mechanistic connection between ER stress and IL-6.

Firstly, the

suppression of PXR by IL-6 and Thaps was determined as a function of the time of
treatment. Secondly, the expression of IL-6 was determined in Thaps-treated primary
hepatocytes. As shown in Fig. 5B, both IL-6 and Thaps significantly decreased PXR
mRNA. However, the decrease by IL-6 occurred sooner than that by Thaps (Fig. 5B).
We next tested whether human primary hepatocytes treated with Thaps actually
support the induction of IL-6.

As shown in Fig. 5C, treatment with Thaps

significantly increased IL-6 mRNA (Fig. 5C).

3.5. Effect of ER-stress on CYP3A4 induction
The enhanced production of IL-6 by Thaps suggested that IL-6 is a contributor to
Thaps-mediated down-regulation of PXR. It is well established that signal transducer
and activator of transcription-3 (STAT3) supports the activity of IL-6 (Bode et al.,
2012). We next tested whether Z-guggulsterone, a blocker of STAT3 (Leeman-Neill
et al., 2009), antagonizes Thaps in down-regulating PXR. On the other hand, Zguggulsterone is a known antioxidant (Chen et al., 2012), therefore, emodin was
included in this study as a control for antioxidant property (Shia et al., 2010). HepG2
cells were treated with Thaps, Z-guggulsterone, emodin or in combination, and then
the level of PXR mRNA was determined. As expected, Thaps significantly decreased
PXR mRNA (Fig. 6A). The decrease, however, was almost completely reversed by Z-
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guggulsterone but not by emodin. It should be noted that Z-guggulsterone and emodin
alone showed no effect on the level of PXR mRNA (Fig. 6A).

Next we tested whether overexpression of PXR itself reverses the effect of Thaps in
terms of the induction of CYP3A4. Both transfected and non-transfected HepG2 cells
were used, and the transfection was performed with a PXR expression construct or the
corresponding vector. The cells were treated with Thaps, rifampicin or both for 24 h
and analyzed for the mRNA level of CYP3A4, a prototypical target of PXR (Klein and
Zanger, 2013). The results were expressed as fold of induction. As shown in Fig. 6B,
Thaps significantly decreased the induction of CYP3A4 in both vector- and
nontransfected cells. However, the decrease was reversed in PXR transfected cells.
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4. DISCUSSION
ER-stress is recognized as a common theme in the development of metabolic
syndrome and other diseases (Johnson et al., 2012; Lin et al., 2012), and emerging
evidence has pointed to decreased capacity of metabolism in liver diseases associated
with ER-stress (He and Chen, 2012; Pagliassotti, 2012). PXR is a master regulator of
genes in xenobiotic elimination. In this study, we have shown that Thaps and BFA,
two well-characterized ER-stressors significantly decreased the expression of PXR.
The decrease was mediated through transcriptional repression and led to reduced
induction of CYP3A4, a prototypical target gene of PXR (Klein and Zanger, 2013).
The decrease of PXR expression by Thaps was reversed by Z-guggulsterone, an active
ingredient of the hypolipidemic herb guggul (Yang et al., 2012).

It is likely that the reversal by Z-guggulsterone was achieved by blocking STAT3
activity. Several lines of evidence support this possibility. Firstly, Z-guggulsterone is
an antioxidant and many antioxidants reportedly protect against ER-stress (Ding et al.,
2012; Li et al., 2012), however, emodin (an antioxidant) showed no reversal activity
on the Thaps-mediated downregulation of PXR (Fig. 6A; Harlev et al., 2012),
excluding an involvement of the antioxidant property in the reversal of PXR
downregulation. Secondly, we have shown that IL-6 and Thaps targeted the same
regulatory sequence (Figs. 2A and 5A) and IL-6 is known to activate the STAT3
signaling pathway (Bode et al., 2012). Thirdly, treatment with Thaps induced the
expression of IL-6 (Fig. 5C), suggesting that increased expression of IL-6 at least in
part plays a role in Thaps-mediated downregulation of PXR. On the other hand, it
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remains to be determined whether increased expression of IL-6 by Thaps represents a
general phenomenon among ER-stressors and diseases associated with ER-stress. The
connection between Thaps and IL-6, nevertheless, provides a mechanistic
understanding of how ER-stress conditions may exert differential effect on the
expression of PXR depending on the increased secretion of cytokines such as IL-6.
STAT3 is a DNA-sequence specific transcription factor (Bode et al., 2012). However,
the PXR promoter regulatory sequence targeted by Thaps and IL-6 does not harbor a
consensus STAT3 element. Instead, this sequence contains two adjacent elements that
were recognized by HNF4 and C/EBP proteins, respectively. It is therefore assumed
that STAT3 decreases the expression of PXR by regulating the expression of HNF4,
C/EBP proteins or both. While it is not clear whether STAT3 down-regulates HNF4,
it was reported that STAT3 up-regulated the expression of C/EBP (Anastasov et al.,
2010). Furthermore, STAT3 was shown to interact directly with C/EBP. Given the
fact that co-transfection of LAP increased PXR expression (Fig. 2C), the STAT3C/EBP complex likely exerts repressive activity. Alternatively, such complex no
longer acts on the PXR promoter, thus functioning as a dominant negative in
comparison with LAP. The C/EBP family has several members and they all bind to
same or similar DNA elements (Tsukada et al., 2011). It is conceivable that other
C/EBP members likely participate in the regulated expression of PXR during ERstress.

One of the interesting findings in this study is the unique interplay between C/EBP
and HNF4. In the reporter experiment, disruption of the HNF4 element almost
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completely eliminated the repressive activity in response to Thaps (Fig. 2B). In
contrast, disruption of the C/EBP element diminished the repression to a much lesser
extent (Fig. 2B). These observations suggested that HNF4 played an essential or a
greater role than a C/EBP protein (probably C/EBP) in supporting the expression of
PXR. However, transfection of HNF4 surprisingly caused less increases of PXR
mRNA than co-transfection of LAP (an active form of C/EBP) (Fig. 2C). One
explanation is that LAP functioned as a transactivator of HNF4 and/or LAP
enhanced the activity of HNF4. In support of the last possibility, LAP was shown to
increase nuclear translocation of HNF4 (Shen et al., 2000).

C/EBP mRNA produces several in-frame translated polypeptides including LAP*,
LAP and LIP. Under normal conditions, LAP is the most abundant form. While LAP*
and LAP are transactivators, LIP acts as a transcriptional repressor (Tsukada et al.,
2011). It is generally accepted that the repressive activity of LIP is achieved by
forming non-functional dimmer with C/EBP activating members and/or a DNAbinding dominant negative. It is also accepted that the relative abundance of various
C/EBP forms (e.g., LAP versus LIP) largely depends on the relative efficiency of the
initiation codons for translation. Interestingly, Thaps treatment caused an 11-fold
increase of C/EBP mRNA (Fig. 3A), and yet the increase in proteins was detected on
LIP but not LAP or LAP* (Fig. 3A). One explanation is that the initiation codon for
LIP was more efficient under ER-stress condition induced by Thaps. It has been
reported that LAP can be converted into LIP (LAP is bigger than LIP) through
proteolytic digestion through an unknown protease. It is likely that such a protease(s)
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is up-regulated and/or activated by Thaps (Welm at el., 1999). Alternatively, LIP was
relatively more stable than LAP in the presence of Thaps (Li et al., 2008).

Nevertheless, EMSA experiment detected increases in DNA binding, apparently by
LIP (Fig. 4B). In contrast, the intensity of the shifted bands by LAP and LAP* was
slightly decreased in nuclear extracts of cells treated with Thaps. Based on ChIP
experiment, however, the increased LIP did not lead to increases in the occupancy of
the C/EBP element in the PXR promoter, although the same antibody was used in both
EMSA and ChIP experiments. One explanation is that chromatin-bound LIP (ChIP)
posed a configuration that hided the epitope from being recognized by this antibody.
Alternatively, LIP normally does not bind to the C/EBP element in the PXR promoter
under the native condition (i.e., cell), although it did so under non-cellular context
(i.e., EMSA). Nonetheless, cotransfection of LIP indeed conferred potent repressive
activity toward the PXR promoter reporter (data not shown).
In summary, our study presents several important conclusions. Firstly, ER-stressors
decreased the expression of PXR and the induction of CYP3A4, pointing to the
possibility of reduced capacity of drug metabolism and detoxication during ER-stress
condition. Secondly, the decreased expression of PXR was a sequence-specific event
through adjacent HNF4-C/EBP elements. Cotransfection of HNF4 or LAP restored
PXR expression, suggesting that factors, altering the activity of these transcription
factors, likely affect the expression of PXR and its target genes. Thirdly, ER-stressors
and IL-6 targeted the same element in repressing PXR, establishing a novel functional
link. This is particularly of significance as such connection suggests that ER-stress
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conditions may vary in suppressing PXR expression depending on the enhanced
secretion of cytokines such as IL-6.
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Table I Sequences of Oligonucleotides

Oligonucleotide

Sequence

Native promoter reporters [numbered according to Kurose et al., Mol Cell Biochem.
(2005) 273:79-85]
PXR-1286-MluI

5'-tcctagccctagcagaatcccatgtggata-3’

PXR-506-MluI

5'-gttctgagatcaaagtggtggggtcacatt-3’

PXR-206-MluI

5'-atttgccactctcttcccct-3’

PXR-106-MluI

5'-atttgctagttcaagtgctg-3’

PXR-56-MluI

5'-gcttagtgcctacatctgac-3’

PXR+14-BamHI

5'-gacaagattgtctcatatccggggaaat-3’

Element reporters
PXR-wild type

5’-gctagttcaagtgctggacttgggacttaggaggggcaatgg-3’

PXR-HNF4 mutant

5’-gctagttcaagtgctggaaccgggacttaggaggggcaatgg-3’

PXR-C/EBP mutant

5’-gctagttcaagtgctggacttgggacttaggattttaccggg-3’

PXR-double mutant

5’-gctagttcaagtgctggaaccgggacttaggattttaccggg-3’

EMSA
PXR-HNF4

5’-tagttcaagtgctggacttgggacttagga-3’

PXR-HNF4(mutant)

5’-tagttcaagtgctggaaccgggacttagga-3’

PXR-C/EBP

5’-cttgggacttaggaggggcaatggagccgcttag-3’

PXR-C/EBP(mutant)

5’-cttgggacttaggattttaccgggagccgcttag-3’
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ChIP
Element sense

5’-gcggatatttgccactctctt-3’

Element reverse

5’-cggatatgagacaatcttgtc-3’

Non-element sense

5’-gagtcttttcattgctacctc-3’

Non-element reverse

5’-tggatgcagagacacagaatg-3’

Semi-quantitative PCR
XBP1-sense

5’-ttacgagagaaaactcatggcc-3’

XBP1-reverse

5’-gggtccaagttgtccagaatgc-3’

GAPDH-sense

5′-agggctgcttttaactctggt-3′

GAPDH-reverse

5′-ccccacttgattttggaggga-3′
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Fig. 1. Effect of Thaps or BFA on the expression of PXR (A) Suppression of PXR
mRNA by BFA and Thaps in HepG2 cell line Cells were treated with Thaps and BFA
at 1 µM or DMSO for 24 h. The level of PXR mRNA was determined by RT-qPCR.
The level of PXR mRNA was normalized according to the level of GAPDH mRNA
and expressed as fold of induction. Asterisk signs indicate statistical significance (P <
0.05). (B) Suppression of PXR mRNA as a function of Thaps HepG2 cells were
treated with Thaps at 0, 1, 10, 50 or 250 nM and the level of PXR mRNA was
determined. Asterisk signs indicate statistical significance (P < 0.05). To ascertain
the magnitude of ER-stress, the presence of spliced XBP1 mRNA was determined by
semi-quantitative RT-PCR with the level of GAPDH mRNA as a control. The PCR
amplification was performed with two pairs of primers designed to target XBP1 and
GAPDH. A preliminary study established that these primers did not interfere with
each other.

(C) Suppression of PXR expression in primary hepatocytes Human

primary hepatocytes (n = 4) were treated with Thaps at 0.1 or 2 µM for 24 h. Total
RNA was analyzed for the level of PXR mRNA by RT-qPCR. Cell lysates (25 µg)
from pooled samples were analyzed by Western blotting for the level of PXR protein.
Asterisk signs indicate statistical significance from the vector (P < 0.05).
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Fig. 2. Repression of PXR reporters and reversal of Thaps-suppression of PXR
expression (A) Repression of PXR promoter reporters HepG2 cells were transiently
transfected by FuGene HD with a mixture containing 50 ng of a reporter, or the vector
along with 5 ng of the null-Renilla luciferase plasmid. The transfected cells were then
treated with DMSO or Thaps at 50 nM for 24 h. Luciferase activities were determined
with a Dual-Luciferase Reporter Assay System and the signals were expressed as
percentages of the normalized luciferase activity of the vector reporter. Below is the
diagram with reported transcription start sites numbered according to Kurose et al
(2005). Asterisk signs indicate statistical significance (P < 0.05). (B) Repression of
PXR element reporters HepG2 cells were transfected with an element reporter (wild
type of a mutant) as described above. Once gain, the luciferase activity was expressed
after normalization. Asterisk signs indicate statistical significance from the wild type
reporter (P < 0.05). (C) Reversal of Thaps-suppression of PXR by LAP or HNF4.
HepG2 cells were transfected with an expression construct (LAP or HNF4) or the
corresponding vector. After an overnight incubation, the transfected cells were treated
with Thaps at 50 nM for 24 h. Cells were collected and total RNA was isolated. The
level of PXR mRNA was determined by RT-qPCR. The level of PXR in vectortransfected and DMSO-treated cells was expressed as 100%. Asterisk signs indicate
statistical significance from the vector (P < 0.05).
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Fig. 3. Effect of Thaps on the expression of HNF4 and C/EBP (LAP*, LAP and
LIP) (A) Effect of Thaps on the expression of C/EBP (LAP*, LAP and LIP) HepG2
cells were treated with Thaps at 50 nM for 12 or 24 h. Cells were collected, total
RNA was isolated and lysates were prepared. The level of C/EBP mRNA was
determined by RT-qPCR (Left). Lysates (20 µg) were resolved by 7.5% SDS-PAGE
and transferred electrophoretically to nitrocellulose membranes.

The blots were

incubated with a carboxylesterase antibody and developed with chemiluminescent
substrate and re-probed by GAPDH antibody. The signal was captured by Carestream
2200 PRO Imager. Asterisk signs indicate statistical significance (P < 0.05). (B)
Effect of Thaps on the expression of HNF4 Cells were treated and samples were
processed as described above. RT-qPCR was performed to determine the level of
HNF4 mRNA whereas Western blotting was performed to determine the level of
HNF4 protein. Asterisk signs indicate statistical significance (P < 0.05).
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Fig. 4. Characterization of HNF4 and C/EBP elements by EMSA and ChIP (A)
EMSA analysis of HNF4 element Nuclear extracts (5 μg) from HepG2 cells treated
with DMSO or Thaps (50 nM) for 24 h were incubated with a biotinylated HNF4
probe for 20 min. In the competition assay, nuclear extracts were pre-incubated with
the unlabeled element (100x), for 20 min, and then incubated with the biotinylated
probe. In disruption assay, nuclear extracts were incubated first with an antibody
against HNF4 on ice for 20 min and then with the biotinylated probe. The proteinDNA complexes were electrophoretically resolved, transferred to a Biodyne® nylon
membrane and located with streptavidin-conjugated horseradish peroxidase and
chemiluminescent substrate. (B) EMSA analysis of C/EBP element Incubations
were performed as characterization of the HNF4 element. However, the C/EBP
probe and an antibody against C/EBP were used. (C) ChIP analysis HepG2 cells
were treated with DMSO or Thaps at 50 nM for 24 h, washed and underwent crosslinking for 15 min by 1% formaldehyde, and the cross-linking was terminated with
125 mM glycine. The soluble chromatins were prepared, pre-cleared with protein G
beads and incubated with an antibody against HNF4 or C/EBP. As a control, the
antibody was replaced with pre-immune IgG. The antibody-bound chromatins and
DNA input (1/20 of the antibody-bound chromatins) were analyzed by PCR for the
presence of the genomic fragment containing the HNF4 and C/EBP adjacent
elements. The location of the primers is shown in the diagram and the sequences of
primers are shown in Table I. All experiments in this figure were performed three
times.
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Fig. 5. Regulated expression of PXR by IL-6 (A) Repression of PXR promoter
reporters by IL-6 and BFA HepG2 cells were transiently transfected as described in
the legend of Figure 2. The transfected cells were then treated with IL-6 (10 ng/ml),
BFA (20 nM) or the corresponding solvent for 24 h. Luciferase activities were
determined with a Dual-Luciferase Reporter Assay System and the signals were
expressed as percentages of the normalized luciferase activity of the vector reporter.
(B) Suppression of PXR mRNA as a function of time of treatment by Thaps and IL-6
HepG2 cells were treated with Thaps at 50 nM, IL-6 at10 ng/ml or the corresponding
solvent for 0-24 h. The level of PXR mRNA was determined by RT-qPCR. Asterisk
signs indicate statistical significance from the corresponding zero-time points (P <
0.05). (C) Effect of Thaps at the level of IL-6 mRNA Primary hepatocytes (n = 4)
were treated with Thaps at 0.1 or 2 µM for 24 h. The level of IL-6 mRNA was
determined. Asterisk signs indicate statistical significance (P < 0.05).
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Fig. 6. Interplay of Thaps with antioxidants and rifampicin (A) Reversal of
Thaps-mediated suppression of PXR by Z-guggulsterone HepG2 cells were treated
Thaps at 50 nM, Z-guggulsterone (10 M), emodin (10 M), or in various
combinations. The treatment lasted for 24 h and the expression of PXR mRNA was
determined by RT-qPCR. The results were from three individual experiments in
triplicate. Asterisk signs indicate statistical significance from the solvent control (P <
0.05). (B) Effect of PXR transfection on the reduced induction of CYP3A4 by Thaps
HepG2 cells were treated with rifampicin (10 M), Thaps (50 nM). Both transfected
and non-transfected cells were used. The transfection was performed with a PXR
expression construct or the corresponding vector. The treatment lasted for 24 h, cells
were collected and total RNA was isolated.

The level of CYP3A4 mRNA was

determined. The results were expressed as fold of induction. Asterisk signs indicate
statistical significance from nontransfected and RIF-treated cells (P < 0.05).
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CHAPTER 4
MANUSCRIPT 2: formatted for the journal of biological chemistry

MicroRNA-30c-1 IS A SILENCER OF THE PREGNANE X RECEPTOR BY
TARGETING THE 3’-UNTRANSLATED REGION AND ALTERS THE
EXPRESSION OF ITS TARGET GENE CYTOCHROME P450 3A4

Abbreviations: CYP3A4, cytochrome P450 3A4; DMEM, Dulbecco’s modified eagle
medium; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; miR, microRNA;
PXR, pregnane X receptor; RT-qPCR, reverse transcription-quantitative polymerase
chain reaction; UTR, untranslated region
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ABSTRACT
The pregnane X receptor (PXR) is a master regulator of genes involved in drug
elimination. Activation of PXR is linked to the development of a spectrum of tumor
behaviors, particularly chemoresistance.

MicroRNAs (miRs) have emerged as

important molecular species involved in tumor progression or suppression. This study
was undertaken to test a large number of oncogenically implicated miRs for their
ability to regulate PXR expression. A total 58 miRs (tumor enhancers or suppressors)
were tested and miR-30c-1 was identified to suppress PXR expression.

The

suppression was achieved by targeting the 3’-untranslated region, 438 nucleotides
from the stop codon.

The suppression was detected in multiple cell lines from

different organ origins. In addition, miR-30c-1 altered the expression of cytochrome
P450 3A4 (CYP3A4), a prototypical target gene of PXR.

The alteration varied

depending on the time and amounts of miR-30c-1. CYP3A4 is responsible for the
metabolism of more than half of drugs in the market. Interestingly, miR-30a, sharing
the seed sequence with miR-30c-1 in the guide strand, failed to suppress PXR,
suggesting that the suppression miR-30c-1 is mediated with the passenger strand. It
has been reported that the expression of miR-30c is low in chemoresistant cell lines.
The interconnection between miR-30c-1 and PXR likely plays an important role in
regulating tumor behaviors, particularly related to chemoresistance.
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1. INTRODUCTION
All organisms are exposed constantly to toxic chemicals from both foreign and endogenous sources. Organisms such as humans have evolved several defensive systems
against chemical insults (Parkinson, 2006). In mammals, these systems are generally
referred to as phase I (Lewis, 2003), phase II (Deenen et al., 2011) and phase III (van
Waterschoot and Schinkel, 2011).

Phase I and II consist of drug-metabolizing

enzymes, whereas phase III is drug transporters. The expression of these genes
undergoes constant changes in response to chemical stimuli. The pregnane X receptor
(PXR, NR1I2) is established as a master transcription factor intimately involved in the
regulated expression of these genes (Krasowski et al., 2005; Ihunnah et al., 2011).
Structurally, PXR belongs to the nuclear hormone receptor superfamily (Timsit and
Negishi, 2007; Ihunnah et al., 2011). Like other nuclear receptors, PXR consists of a
variable N-terminal domain, a highly conserved DNA-binding domain, a hinge region
and a multifunctional C-terminal ligand-binding domain (Timsit and Negishi, 2007).
The DNA-binding domain recognizes the canonical sequence AGG/TTCA (Modica et
al., 2009). The major portion of the ligand-binding domain is helical in structure, and
the C-terminal helix (helix 12) is directly involved in switching from repressing to
activating status of a target gene (Carnahan and Redinbo, 2005). Binding to an
agonist induces conformational changes of this helix, leading to a platform favoring
association with coactivators, namely transactivation.

The expression of PXR itself, like its target genes, is drastically altered by certain
xenobiotics and disease conditions (Sachdeva et al., 2003; Song et al., 2004; Ma et al.,
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2005; Shi et al., 2010). For example, the hypolipidemic agent clofibrate and synthetic
glucocorticoid dexamethasone have been shown to induce PXR (Ma et al., 2005; Shi
et al., 2010). The induction synergistically increased the expression of cytochrome
P450 3A genes (CYP3A) (Shi et al., 2010), the prototypical targets of PXR (Timsit
and Negishi, 2007).

Dexamethasone induced PXR in both rodents and humans

(Cooper et al., 2008; Shi et al., 2010). Proinflammatory stimuli, on the other hand,
have been shown to suppress the expression of PXR (Sachdeva et al., 2003; Yang et
al., 2010). The level of PXR mRNA was rapidly decreased in rodents treated with
lipopolysaccharide, a potent immunostimulant (Sachdeva et al., 2003). In human
hepatocytes, pro-inflammatory cytokine interleukin-6 markedly reduced the levels of
PXR mRNA (Yang et al., 2010). The suppression was accompanied by reduced
induction on the expression of PXR-regulated genes such as CYP3A23 (Beigneux et
al., 2002; Sachdeva et al., 2003).

While transactivation and repression are recognized the major mechanisms in the
regulated expression of PXR (Ma et al., 2005; Shi et al., 2010; Yang et al., 2010),
post-transcriptional mechanisms have been increasingly implicated in the regulated
expression of this nuclear receptor.

MicroRNA (miR)-148a reportedly down-

regulated PXR post-transcriptionally, manifested by a significant induction of PXR
mRNA (Takagi et al., 2008). On the other hand, miRs are important regulators in a
wide spectrum of diseases including malignancies and metabolic syndrome (Rottiers
and Näär, 2012; Kim and Reitmair, 2013; Yu et al., 2013). These diseased conditions
are inherently interconnected with inflammatory process, although the magnitude of
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inflammation may vary depending on the stage of diseases (Ranjha and Paul, 2013).
Interestingly, the majority of studies with human malignant tissues indicated increases
in PXR expression, and activation of PXR has been associated with the development
of a wide spectrum of tumor behaviors, particularly chemoresistance (Pondugula and
Mani, 2013).

In this study, we took a comprehensive approach and tested a large number of miRs
for their ability to regulate PXR expression.

These miRs are implicated in the

development of cancer, inflammation or both. A total 58 miRs were tested and miR30c-1 was identified to suppress PXR. The suppression was achieved by targeting the
3’-untranslated region (UTR) and detected in multiple cell lines from different organ
origin. Importantly, miR-30c-1 was shown to alter the expression of CYP3A4, a
prototypical target gene of PXR. CYP3A4 is responsible for the metabolism of more
than half medicines and many chemotherapeutic agents are PXR activators.
Therefore, the PXR and miR-30c-1 connection is likely a major determinant in
regulating tumor behaviors, particularly related to chemosensitivity.
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2. MATERIALS AND METHODS
2.1. Plasmid constructs
All miR precursor clones were purchased from System Biosciences Inc (Mountain
View, CA). The CYP3A4-DP-Luc reporter was described in our previous publication
(Song et al., 2005). The PXR cDNA reporters harboring a 3’-UTR segment were
prepared with the pGL3 promoter vector (Promega, Madison, WI) through Xba I and
Fse I restriction endonuclease sites. The 3’-UTR segments were amplified by PCR
with high fidelity Platinum Taq DNA polymerase (Life Technology Co., Carlsbad,
CA). A cDNA clone encoding human PXR, used as the PCR template, was described
elsewhere (Song et al., 2004). The PXR 3142/3691Luc and 3690/4408Luc reporters
were prepared initially and the PXR 3142/3691Luc reporter was used as the template
for preparing deletion mutants at 5’ end. The primers for PCR amplification are listed
in Table I. All reporter constructs were subjected to sequence analysis.

2.2. Cell transfection and luciferase assay
Three cell lines were used in this study including 293T (human embryonic kidney),
HepG2 (human hepatocellular carcinoma) and LS180 (human colon adenocarcinoma).
HepG2 and LS180 lines were purchased from American Type Culture Collection
(Manassas, VA), but the 293T line was from GenHunter Corporation (Nashville, TN).
All cell lines were maintained in Dulbecco’s modified eagle medium (DMEM)
containing 10% fetal bovine serum, penicillin and streptomycin, 1x non-essential
amino acids. Unless otherwise indicated, cells were plated in 48 well-plates and
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transiently transfected by GenJet version II from SignaGen Laboratories (Rockville,
MD). For reporter assays, the transfection mixture typically contained 50 ng of a
reporter, 50 ng of a miR construct and 5 ng of the null-Renilla luciferase plasmid.
After incubation at 37C for 24 h, cells were extensively washed, collected and
assayed for luciferase activities with the Dual-Luciferase Reporter Assay System as
described previously (Song et al., 2004; Yang et al., 2011). The reporter luciferase
activity was normalized with Renilla luciferase activity, and the vector-transfected
cells served as the basal reporter activity for miRs-transfected cells. It should be noted
that the same amount of total plasmids were used in all reporter assays.

2.3. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
The LS180 cell line was primarily used for the RT-qPCR and because this cell line
expresses high-levels of PXR and has been shown to robustly support PXR-directed
transactivation (Zheng et al., 2012). Cells were typically plated in 24-well plates for
overnight and then transfected with the miR-30c-1 construct or the corresponding
vector. Cells were harvested 72 or 96 h after the transfection. In some cases, cells
were treated with DMSO or rifampicin (10 M) after transfection. Harvested cells
were used for the preparation of total RNA.

For the determination of PXR or

CYP3A4 mRNA, total RNA (1 g) was subjected to the synthesis of the first strand
cDNA as described previously (Xiao et al., 2012). cDNAs were then diluted 8 times
and RT-qPCR was conducted with TaqMan Gene Expression Assay (Applied
Biosystems, Foster City, CA). The TaqMan probes were: PXR, Hs00243666_m1;
CYP3A4, Hs00604506_m1; glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
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4352934E; and RNA polymerase II, Hs00172187_m1. The PCR amplification was
conducted in a total volume of 20 l containing universal PCR master mixture (10 l),
gene-specific TaqMan assay mixture (1 µl), and cDNA template (6 l). The mRNA
levels were normalized according to the level of GAPDH and the normalization of
selected samples was confirmed based on the signal of RNA polymerase II.
Amplification and quantification were done with the Applied Biosystems 7500 RealTime PCR System.
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3. RESULTS
3.1. Identification of miR-30c-1 as a suppressive miR of PXR
PXR is a master regulator of gene expression and has been known to modulate the
tumor behaviors, particularly related chemoresistance (Pondugula and Mani, 2013).
Like its target genes, we and other investigators have shown that the expression of
PXR is regulated by factors such as age and therapeutic agents (Pascussi et al., 2000;
Ma et al., 2005; Vyhlidal et al., 2006; Shi et al., 2010). While transactivation and
repression are involved in regulated expression of PXR, emerging evidence suggests
an involvement of post-transcriptional mechanisms, particularly through miR species
(Takagi et al., 2008). miRs constitute a superfamily of small RNA species, and many
of them are implicated in the development of various types of tumor behaviors
(Rottiers and Näär, 2012; Kim and Reitmair, 2013; Yu et al., 2013). To shed light on
the missing link between PXR expression and miRs, we tested a large number of miRs
(cancer enhancers or suppressors) for their ability to regulate the expression of PXR.
Some of the miRs are known to regulate inflammatory reaction.

We took the

advantage of miRs as predominantly post-transcriptional regulators (Kim and
Reitmair, 2013; Yu et al., 2013), mRNA-based PXR reporters (cDNA reporters) were
used for the initial study.

While there are exceptions, miRs usually target the 3’-UTR sequences. Therefore, we
constructed two luciferase reporters that together harbor the entire 3’-UTR sequence
of the dominant human PXR transcripts (Fig. 1A) (NM_003889). These two reporters
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were

designated

PXR3142/3691Luc

and

PXR3690/4408Luc,

respectively.

Cotransfection was performed in 293T cells to determine the effect of a miR on the
reporter activity.

In addition, a renilla luciferase construct was included in the

transfection. As shown in Fig. 1B, all miRs, with an exception of miR-30c-1, affected
the activity of both reporters to a similar extent. Transfection of miR-30c-1, compared
with the vector, resulted in decreased activity of PXR3142/3691Luc by 50%, but only
10% decrease on the activity of PXR3690/4408Luc. Some miRs such as miR-26A-2,
compared with the vector, caused significantly increases in the activity of both
reporters. Some others such as miR-433 significantly decreased the activity of both
reporters (Fig. 1B). These miRs generally affected the renilla luciferase activity,
which was used for normalizing transfection efficiency.

3.2. Sequence-specific targeting by miR-30c-1 independently of cell types
The screening study clearly demonstrated that human PXR mRNA is a sequencespecific target of miR-30c-1. To locate the sequence that supports the action of this
miR, a serial of deletions from the 5’ end were made on the PXR3142/3691Luc
reporter and the resultant reporters were tested for the lost activity toward miR-30c-1.
As shown in Fig. 2A, all deletion mutants, except PXR3592Luc and PXR3642Luc,
were repressed by miR-30c-1. These results established that the 50 base pairs, namely
from 3542 to 3592 support the repression of miR-30c-1 on PXR expression. We are
in the process of specifying the precise sequence and nucleotides that support the
action of miR-30c-1 by site-directed mutagenesis.
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It is well known that some miRs are processed in a cell-specific manner (Finnegan and
Pasquinelli, 2013). We next tested whether the repression by miR-30c-1 occurs in
HepG2 and LS180 cell line. HepG2 was derived from hepatocellular carcinoma
whereas LS180 from colon adenocarcinoma. Importantly, both organs abundantly
express PXR (Lehmann et al., 1998; Zhang et al., 1999).

In addition, the

cotransfection was performed with various amounts of miR-30c-1 to establish the
concentration-response relationship.

As expected, the PXR3542Luc but not

PXR3592Luc reporter was repressed in both cell lines (Fig. 2B).
supported greater repression than LS180 cells.

HepG2 cells

Overall, the magnitude of the

repression occurred in a concentration-dependent manner (Fig. 2B).

3.3. Effect of miR-30c-1 on the expression of CYP3A4
The study with the reporters established that the action of miR-30c-1 on PXR
suppression is sequence-specific but not cell-specific (Kim and Reitmair, 2013; Yu et
al., 2013). Next we tested whether the repressive activity of the reporter can be
recaptured on the expression of the endogenous gene of PXR. Initially, cells were
transfected with miR-30c-1 or the corresponding vector, cultured for various lengths
of time, and the levels of PXR mRNA were determined. Fig. 3A shows representative
results of this study.

The level of PXR mRNA was decreased in miR-30c-1

transfected cells, and the 96 h time-point showed less decrease than the 72 h timepoint (Left of Fig. 3A). The decrease in cells transfected with 20 ng plasmid of miR30c-1 was less profound than that in cells transfected with 200 and 800 ng.
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Nonetheless, 200 and 800 ng caused a comparable decrease in both time-points. Next
we tested whether miR-30c-1 alters the mRNA level of CYP3A4, a prototypical target
of PXR (Klein and Zanger, 2013). While miR-30c-1 caused changes in the level of
CYP3A4 mRNA, the changes varied depending on the amount of miR-30c-1 plasmid
used for the transfection as well as the time after the transfection (Fig. 3A, Right). At
the 72 h time-point, cells transfected with the miR-30c-1 plasmid at 20 and 200 ng
exhibited increases in CYP3A4 mRNA, whereas a slight decrease was detected in
cells transfected with 800 ng. At the 96 h time-points, significant decreases were
detected in cells transfected with 200 and 800 ng plasmid (Fig. 3A, Right).

We next tested whether miR-30c-1 also alters the induction of CYP3A4. Cells were
transfected with miR-30c-1 or the vector, and then treated with DMSO or rifampicin, a
prototypical activator of human PXR.

As shown in Fig. 3B (Left), the overall

expression of CYP3A4 mRNA was decreased at both basal and induced level with an
exception of the basal level in cells transfected with 20 ng plasmid of miR-30c-1. As
described above, marked decreases in basal expression were detected in cells
transfected with miR-30c-1 at 200 and 800 ng. As a result, these cells showed no
changes in terms of fold of induction (Fig. 3B, Right). To further establish the role in
reduced induction of CYP3A4, a CYP3A4 reporter was tested for the reduced
activation in response to miR-30c-1 (Song et al., 2005). Consistent with the result on
the level of CYP3A4 mRNA, cotransfection of miR-30c-1 decreased the activation of
this reporter by as much as 60% (Fig. 3C).
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4. DISCUSSION
PXR has been established to play a major role in the expression of genes involved in
drug elimination (Krasowski et al., 2005). However, emerging evidence has suggested
that this nuclear receptor, in addition to drug elimination, is integrally connected with
endobiotic signaling and homeostasis of energy balance (Ihunnah et al., 2011). While
PXR is recognized as a master regulator of gene expression, we and other
investigators have reported that the expression of PXR is regulated as well (Pascussi et
al., 2000; Ma et al., 2005; Vyhlidal et al., 2006; Shi et al., 2010).

Multiple

mechanisms are reportedly involved in the regulation of PXR expression including
transactivation, repression and miR-148a silencing (Takagi et al., 2008). This study
identified and characterized miR-30c-1 as a silensor of PXR. A set of experiments
have shown that miR-30c-1 targeted the PXR 3’-UTR and decreased the level of PXR
mRNA, suggesting that miR-30c-1 suppresses PXR by decreasing the mRNA stability
of this nuclear receptor. Importantly, this miR altered the expression of CYP3A4, a
prototypical target of PXR (Klein and Zanger, 2013), pointing to the functional
consequences of miR-30c-1 drug elimination.

miR-30c-1 belongs to the miR-30 family, and the human genome has six miR-30
genes (Lewis et al., 2003; Bridge et al., 2012). However, these genes produce only
four distinct mature guide strands. Importantly, these guide strands have the identical
seed sequence, allowing them to regulate the expression of the same target genes, at
least through the guide strand. This study, however, has demonstrated that miR-30a, a
member of this family, failed to suppress the PXR reporters (Fig. 1B), suggesting that
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miR-30c-1 uses the passenger strand to target the PXR sequence. In addition to miR30c-1, the miR-30c class has another member, namely miR-30c-2 (Karbiener et al.,
2011). Both miRs are derived from intronic sequences of other genes. The miR-30c-1
gene is located at chromosome 1 and the miR-30c-2 gene is located at chromosome 6.
Importantly, miR-30c-1 and miR-30c-2 differ in the sequence of their passenger strand
(Fig. 4A). Interestingly, the passenger strand of miR-30c-2 matches better than that of
miR-30c-1 with the PXR 3-UTR region (Fig. 4A). Therefore, it is likely that miR30c-2 is more potent than miR-30c-1 in silencing PXR, although the relative
expression of these two miRs likely determines their contribution to PXR silencing.
In addition to miR-30c-2, miR-148a, another miR, reportedly silenced PXR (Takagi,
2008).

Based on the recognition sequences (Fig. 4B), both miR-30c and miR-148a

target the same RNA species of PXR, although their recognition elements are 218
nucleotides apart (Fig. 4B). Nevertheless, it remains to be determined whether and
how miR-148a networks with miR-30c in terms of regulating PXR expression.

The suppression of PXR by miR-30c-1 may have important clinical consequences. In
this study, we have shown that miR-30c-1 decreased the level of PXR mRNA
accompanied by altered expression of CYP3A4, a prototypical gene of PXR (Klein
and Zanger, 2013). The altered expression of CYP3A4, however, varied depending on
time and the amounts of miR-30c-1. The overall expression of CYP3A4 mRNA was
decreased under both basal and induction conditions (Fig. 3B, Left), but the decrease
was not evident until later time-point (Fig. 3A, Right). Many investigators reported
delayed response in miR-mediated suppression (Haenishch et al., 2011). The altered
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expression of CYP3A4 by miR-30c-1 was in particular as it represented a mechanism
secondarily to the suppression of PXR. Such an indirect mechanism required longer
time to achieve the anticipated effect. On the other hand, the basal level of CYP3A4
mRNA at the early time-point was actually increased when small amounts of miR30c-1 were used (Fig. 3A, Right). The precise mechanism on the increase remains to
be determined. Nuclear receptors including PXR are known to interact with corepressors and coactivators (Carnahan and Redinbo, 2005). It is the presence of a
ligand that induces conformational changes from repressing to activating status of a
target gene.

The functionality of PXR has been linked to a wide range of behavior changes of
malignancy and some of them are opposing to each other (Pondugula SR, Mani,
2013). In some cases, activation of PXR up-regulates the expression of proapoptotic
genes thus shows tumor suppressive activity.

In other cases, PXR is linked to

upregulation of antiapoptotic genes and favors tumor progression. Nevertheless, upregulated expression of genes involved in drug eliminations is generally considered to
be a major contributing factor to the development of chemoresistance. Interestingly,
miR-30c has been shown to promote cell apoptosis, inhibit cell proliferation, reduce
tumor clonogenicity and suppress metastatic potentials (Li et al., 2012; Bockhorn et
al., 2013). In addition, the expression of miR-30c was significantly decreased in many
chemoresistant cell lines (Sorrentino et al., 2008).
whether

miR-30c

members

can

overcome
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It remains to be determined

PXR-directed

chemoresistance.

Interestingly, miR-148a, another silencer of PXR, has also been down-regulated in
advanced cancer (Takahashi et al., 2012).

In summary, our study presents several important conclusions. Firstly, identification
of miR-30c-1 as a negative regulator of PXR, along with the previous reporter on
miR-148a, points the existence of a miR-network in regulating the functionality of
PXR.

Secondly, miR-30c-1 but not miR-30a suppressed PXR, underscoring the

importance of the passenger strand in gene silencing. Thirdly, activation of PXR has
been closely linked to the development of a spectrum of tumor behaviors, particularly
in chemo resistance. miR-30c and miR-148a, on the other hand, have been associated
with less aggressive behaviors of malignancy.

These findings suggest that miR-

30c/miR-148a-PXR represents favorable outcomes of chemotherapy, particularly
those with a potent activating activity of PXR.
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Table I Sequences of Oligonucleotides

Oligonucleotide

Sequence

PXR3142/3691Luc (XbaI)

5’-tgagcggctgcccttggg-3’

PXR3142/3691Luc (FseI)

5’-agaggactcccacagata-3’

PXR3690/4408Luc (XbaI)

5’-ggagtcctctagagagatgagaagccagga-3’

PXR3690/4408Luc (FseI)

5’-gtacattatttaattcct-3’

PXR3192/3691Luc (XbaI)

5’-gccctctgagccgccact-3’

PXR3242/3691Luc (XbaI)

5’-gacaatgccctgctggcc-3’

PXR3292/3691Luc (XbaI)

5’-ggctagcattcctcagga-3’

PXR3342/3691Luc (XbaI)

5’-ctgtagggagtgaagcca-3’

PXR3392/3691Luc (XbaI)

5’-aggtcaggaccatcagag-3’

PXR3442/3691Luc (XbaI)

5’-tgtggtctggggagaaat-3’

PXR3492/3691Luc (XbaI)

5’-aagggaccaagcgaccaa-3’

PXR3542/3691Luc (XbaI)

5’-ccacgtttgttcgcttcc-3’

PXR3592/3691Luc (XbaI)

5’-gtctcccacttcccactc-3’

PXR3642/3691Luc (XbaI)

5’-tccaggcctgtactcatc-3’

Numbered according to NM_003889.
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Fig. 1. Suppression of PXR reporters derived from the 3’-untranslated region
(UTR) (A) Diagrammatic presentation of PXR reporters The PXR3142/3691Luc
reporter contains the cDNA segment from nucleotide 3142 to 3691, whereas the
PXR3690/4408Luc reporter contains from nucleotide 3690 to 4408. The hatched box
represents the luciferase coding sequence. (B) Identification of PXR suppressive
miR(s) Cells (293T) were transiently transfected by GenJet version II with a mixture
containing 50 ng of a miR precursor construct, 50 ng of a reporter, or the vector along
with 5 ng of the Renilla luciferase plasmid. The transfected cells were cultured for 24
h, harvested and analyzed for luciferase activities with a Dual-Luciferase Reporter
Assay System. The results were from one of two experiments in triplicate.
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Figure 1 (Vachirayonstien, 2013)
101

Fig. 2. Characterization of miR-30c-1 on the suppression of PXR (A) Dissection of
The PXR3142/2691Luc reporter for the identification of miR-30c-1 response Cells
(293T) were transiently transfected by GenJet version II with a mixture containing 50
ng of the miR-30c-1 construct, 50 ng of a reporter, or the vector along with 5 ng of the
Renilla luciferase plasmid. The transfected cells were cultured for 24 h, harvested and
analyzed for luciferase activities with a Dual-Luciferase Reporter Assay System. (B)
Suppression of PXR3542/3691Luc by miR-30c-1 in HepG2 and LS180 cell lines Cells
were transfected by GenJet version II with a mixture containing 5-150 ng of the miR30c-1 construct, 50 ng of a reporter (PXR3542/3691 or PXR3592/3691Luc, or the
vector along with 5 ng of the Renilla luciferase plasmid. The vector plasmid was used
to equalize the total amount of constructs. The transfected cells were cultured for 24
h, harvested and analyzed for luciferase activities as described above. Asterisk signs
indicate statistical significance (P < 0.05).
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Fig. 3. Effect of miR-30c-1 on the expression of CYP3A4 (A) Effect of miR-30c-1
on the expression of PXR and CYP3A4 Cells (LS180) were transfected by GenJet
version II with the miR-30c-1 construct at 20, 200 and 800 ng. The vector plasmid
was used to equalize the total amount of constructs. Cells were harvested 72 or 96 h
post-transfection. Total RNA was isolated and the mRNA levels of PXR (Left) and
CYP3A4 (Right) were determined by RT-qPCR. All experiments were performed
three times in triplicate. Asterisk signs indicate statistical significance from vectortransfected cells (P < 0.05). (B) Effect of miR-30c-1 on the induction of CYP3A4
Cells (LS180) were transfected as described above and treated with DMSO or 10 M
rifampicin (RIF) 72 h post-transfection.

The treated cells were collected 24 h

thereafter and the level of CYP3A4 mRNA was determined by RT-qPCR.
experiments were performed three times in triplicate.

All

Asterisk signs indicate

statistical significance from vector-transfected cells or cells treated with DMSO (P <
0.05). (C) Effect of miR-30c-1 on the activation of CYP3A4-DP-Luc reporter Cells
(LS180) were plated in 48 well-plates and transfected with a mixture containing 100
ng of the CYP3A4-DP-Luc reporter, 10 or 100 ng of miR-30c-1 or the vector along
with the PXR expression plasmid and 5 ng of the Renilla luciferase plasmid. The
vector was used to equalize the total amount of constructs. After incubation at 37C
for 24 h, the transfected cells were treated with 10 M rifampicin (RIF) or the same
volume of DMSO for 48 h. Luciferase activities were determined with a DualLuciferase Reporter Assay System and the reporter activity was normalized based on
the Renilla luminescence signal. All experiments were performed three times in
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triplicate. Asterisk signs indicate statistical significance from vector-transfected and
RIF-treated cells (P < 0.05).
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Fig. 4. Sequence targeted by miR-30c-1 and its location in the 3’-UTR of PXR
transcript (A) Sequence targeted by miR-30c-1 The sequence potentially targeted by
miR-30c is identified by xx. Both miR-30c-1 and miR-30c-2 are shown as the
passenger strand. (B) Location of the sequence targeted by miR-30c In addition to
the location of the sequence targeted by miR-30c, the location of the sequence targeted
by miR-148a is also shown. Specifically, miR-30c (both 30c-1 and 30c-2) likely
targets the sequence from nucleotide 3583 to nucleotide 3660, whereas miR148a from
3359 to 3386, respectively. The sequence is numbered according to NM_003889.
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CHAPTER 5 CONCLUSION
PXR is the master regulator of xenobiotic clearance. PXR regulates the
expression of important genes in xenobiotic metabolism. CYP3A4, which metabolizes
approximately 50% of marketed drugs, is mainly regulated by PXR (Guengerich, 2003
and Redinbo, 2004). Various diseases such as steatosis, diabetes, liver cancer, and
viral infections are known to affect the expression of CYP3A4 and other PXR target
genes. As a result, drug metabolism and elimination are altered in these conditions. ER
stress and unfolded protein response is profoundly involved in the diseases. Thus, the
effect of ER stress on PXR was studied to understand the consequences of ER stress
on the expression of PXR and CYP3A4.

Effect of ER stress on PXR expression
ER stressors thapsigargin and brefeldin A caused ER stress in human
hepatocytes and HepG2 cells, leading to down-regulation of PXR and reduced
induction of CYP3A4. The expression of PXR was repressed at the transcriptional
level. The promoter study revealed that HNF4α and C/EBPβ bound to the promoter
region of PXR. Thapsigargin decreased HNF4α protein level whereas increased
C/EBPβ LIP level. It is known that HNF4α generally functions as a positive
transcriptional regulator and C/EBPβ LIP represses transcription of target genes
(Cereghini 1996, Schrem et al., 2002, and Tsukada et al., 2011). Therefore, downregulation of HNF4α and up-regulation of C/EBPβ LIP contributed to reduced
transcription of PXR. The reporter assay showed that mutation at the HNF4α binding
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site abolished the repressive effect of thapsigargin. Overexpression of HNF4α or
C/EBPβ LAP alone in the HepG2 cells treated with thapsigargin returned PXR mRNA
to the normal level. The EMSA experiment showed that HNF4α bound to the
promoter region of PXR and the binding decreased once HepG2 cells were treated
with thapsigargin. The experiment proved that HNF4α bound to the binding site and
thapsigargin-induced ER stress decreased HNF4α protein level and thus decreased
bounded HNF4α. The ChIP assay also showed that HNF4α bound to the binding site
in living cells and the binding of HNF4α decreased in thapsigargin-treated cells. Both
the EMSA and ChIP assay showed that C/EBPβ bound to the binding site next to the
HNF4α binding site. Thus, C/EBPβ would also contribute to the expression of PXR.
Thapsigargin-induced ER stress up-regulated IL-6 expression in human
hepatocytes. IL-6 repressed the expression of the reporters at the same sequences as
thapsigargin. This finding suggested that IL-6 involved in repression of PXR by
thapsigargin. IL-6 is a pro-inflammatory cytokines, inducing acute or chronic
inflammation which involves in several diseases such as viral infections and liver
cancer (Neurath et al., 2011 and Sun et al., 2012). Many P450 enzymes are known to
down-regulated during inflammation. Thus, the evidence that thapsigargin induced IL6 showed that there were connection between ER stress and inflammation which led to
down-regulation of PXR and CYP3A4.
The study showed that ER stress induced by ER-stressors decreased PXR
expression and PXR-mediated induction of CYP3A4. The reduction of CYP3A4
induction in ER stress could diminish capability to metabolize and eliminate drugs,
which could affect drug toxicity and efficacy. ER stress was connected to
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inflammation through the pro-inflammatory cytokine IL-6. Thus, diseases such as
steatohepatitis, viral infections, and cancer in the state that involves ER stress and
inflammation would decrease PXR expression.

miRNA regulating PXR
miRNAs are recognized as important regulators of gene expression at the posttranscriptional level. In human, more than 1000 miRNAs have been identified.
However, target genes of many of these miRNAs are not known and one miRNA
tends to interact with more than one mRNA. In addition, a gene can be regulated by
several miRNAs. Thus, miRNAs play important roles in regulating protein coding
gene. Identifying miRNA that targets a gene of interest is challenging because factors
that dictate binding between miRNA and the gene are not well understood. In this
study, miR-30c-1 was identified to interact with the 3’-UTR of PXR. The potential
binding site of miR-30c-1 was located based on the computational analysis and the
reporter assay. Overexpression system showed that miR-30c-1 decreased PXR mRNA
level, suggesting that miR-30c-1 decreased stability of PXR mRNA. In the reporter
system, miR-30c-1 reduced CYP3A4 induction by PXR. The miRNA also altered the
basal expression of CYP3A4.
The present study showed that PXR was regulated by miR-30c-1. The miRNA
decreased the expression of PXR and the CYP3A4 induction. Thus, miR-30c-1 may
contribute to alteration in drug metabolism. Since the miRNA regulated the expression
of PXR, the expression of miR-30c-1 is likely to affect the PXR expression. At
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present, the regulation on the expression of miR-30c-1 is not known. miR-30c-1 might
be related to diseases or biological conditions that could eventually affect PXR
expression.
In summary, the studies showed that ER stress down-regulated the expression
of PXR and reduced PXR-mediated CYP3A4 induction. The transcription of PXR was
repressed. Decreasing of HNF4α and increasing of C/EBPβ LIP were shown to be the
mechanism of repression. Since HNF4α and C/EBPβ bound to the promoter region of
PXR, alteration in the levels of HNF4α and C/EBPβ in other conditions would also
affect the expression of PXR. The transcriptional activation of CYP3A4 was
decreased in ER stress due to reduction of PXR. Inflammation is known to downregulated CYP3A4 and some other P450s enzymes and impair drug metabolism.
Many of them are the PXR target genes. The pro-inflammatory cytokine IL-6 was also
induced during ER stress, proving the link between ER stress and inflammation. Thus,
ER stress could affect drug toxicity and efficacy. PXR was also regulated by miR-30c1. The miRNA down-regulated the expression of PXR at the specific binding site on
the 3’-UTR. Both the basal expression and induction of CYP3A4 were altered by
miR-30c-1. Thus, miR-30c-1 affected both the expression and function of PXR and
may contribute to alteration in drug metabolism.
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